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Abstract 
 
Budded virions of AcMNPV can enter a variety of non-host cells, a characteristic likely 
due to the presence of GP64, an envelope protein found on a small subset of 
baculoviruses.  Results show that AcMNPV's tropism for vertebrate cells can be restricted 
- a prerequisite for using AcMNPV for targeted in vivo gene delivery - by replacing the 
gp64 gene with SeF from SeMNPV.  Unlike the relatively well characterized GP64 
protein, the significance and function of the F homolog (Ac23, a pathogenicity factor), is 
poorly understood.  How Ac23 might contribute to the faster speed of kill was examined 
by comparing occlusion bodies and occlusion-derived virions (ODV) of Ac23null mutant 
viruses with control viruses at the ultrastructural level.  The results show that Ac23null 
mutant produces a significantly higher percentage of ODVs with single or lower number 
of nucleocapsids than controls, suggesting Ac23 may play a role in multicapsid 
envelopment of ODVs. 
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Chapter 1 – Introduction of baculovirus 
 
1.1 Baculovirus overview. 
 
1.1.1 Structure and classification. 
The Baculoviridae is a large family of enveloped viruses that are pathogenic to 
arthropods, primarily insects of the orders Lepidoptera, Hymenoptera, and Diptera 
(Federici, 1999).  Baculoviruses have a large, double-stranded, covalently closed, circular 
DNA genome (Summers and Anderson, 1972).  The size of the genome varies between 
species and can range from 80-180 kilobase (kb) in length (Burgess, 1977).  The baculo 
portion of baculovirus refers to the rod-shaped nucleoprotein complex called 
nucleocapsids found in the viral particles (virions).  Baculovirus nucleocapsids are 
typically 40-50 nm in diameter and 200-400 nm in length (Harrap, 1972), but can be 
extended to accommodate the larger genomes found in recombinant viruses carrying 
large inserts (Fraser, 1986).  Baculoviruses are currently divided into two genera: 
Nucleopolyhedrovirus (NPV) and Granulovirus (GV).  NPV virions could either contain 
a single nucleocapsid (single nucleopolyhedrovirus, SNPV) or multiple nucleocapsids 
(multiple nucleopolyhedrovirus, MNPV) depending on the viral species (Theilmann et 
al., 2005), while GV virions contain a single copy of the viral genome in a single 
nucleocapsid.    Recently, a new classificantion was proposed based on phylogenetic 
evidence and further biological and morphological characteristics (Jehle et al., 2006). The 
family Baculoviridae was subdivided into four genera: Alphabaculovirus, 
Betabaculovirus, Gammabaculovirus, and Deltabaculovirus. 
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1.1.2 Infection cycle of AcMNPV. 
Among the baculoviruses, the infection cycle of the type baculovirus Autographa 
californica multicapsid nucleopolyhedrovirus (AcMNPV) is best characterized.  In a 
single AcMNPV infection cycle, virions with two distinct phenotypes and functions are 
produced.  Budded virus (BV) are formed early in the infection cycle when nucleocapsids 
assembled in the nucleus are transported to the plasma membrane, and acquire an 
envelope by budding from the plasma membrane of the infected cell.  The envelopes of 
BV contain envelope fusion proteins that mediate virus entry into cells by adsorptive 
endocytosis (Volkman and Goldsmith, 1985; Wang et al., 1997).  BVs are capable of 
infecting most cell types within a susceptible host and are thus responsible for spreading 
the infection systematically within a host.  In the late phase of infection, nucleocapsids 
are no longer transported to the plasma membrane, but are enveloped within the nucleus 
to form occlusion-derived viruses (ODV).  ODVs are eventually occluded in a matrix of 
polyhedrin protein to form an occlusion bodies (OB).  OBs are released from the infected 
cells when the cell lyses, and the polyhedrin matrix is believed to protect ODVs from 
detrimental environmental and chemical insults, and help preserve ODV infectivity in the 
field.  Upon ingestion of OBs by a susceptible host, OBs dissolve in the host’s midgut, 
releasing the ODVs which are highly infectious to midgut epithelial cells.  Thus, ODVs 
are the virion phenotype that is responsible for infection of larval arthropods in the field 
and for host to host transmission of viral infection.   
 
1.1.3 AcMNPV-based protein expression system. 
AcMNPV has become an important tool in both basic and applied research.  The most 
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common application of AcMNPV to date is its use as a tool for expression of recombinant 
proteins.  Two decades ago, AcMNPV was first used as an expression vector to express 
human beta interferon in insect cells (Smith et al., 1983).  Since then, numerous 
recombinant proteins have been produced using the baculovirus-insect cell expression 
system.  Baculovirus expression vector (BEV) system is considered one of the best tools 
currently available for the expression of recombinant genes in a eukaryotic host.  Unlike 
prokaryote-based expression systems, the eukaryote-based BEV system can produce 
proteins that are post-translationally modified by proteolytic cleavages, glycosylation, 
and phosphorylation (Jarvis, 1997).  The foreign gene to be expressed is usually placed 
under the transcriptional control of a strong viral promoter such as the p10 or polyhedrin 
promoter, which enables the expression of the gene after viral infection of the host cells.  
In addition to the hundreds of different recombinant proteins which have been produced 
using the BEV system for research use, this system is now being used for the production 
of more than two dozen pharmaceutical proteins and vaccines that are either 
commercially available or undergoing clinical trials.  For example, a BEV is used in the 
manufacture of human vaccines such as GlaxoSmithKline’s cervical cancer vaccine 
Cervarix®, and Protein Sciences Corp.’s influenza vaccine FluBlokTM, as well as animal 
vaccines such as Intervet’s Porsilis® Pesti for Classical Swine Fever, and porcine 
circovirus 2 vaccines Circumvent® PCV and Porcilis® PCV. 
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1.2 Baculovirus as a vector for gene delivery into mammalian cells. 
 
1.2.1 Discovery of AcMNPV transduction of mammalian cells. 
Volkman and Goldsmith (1983) first showed that AcMNPV can be taken up efficiently by 
non-target vertebrate cells such as human lung carcinoma cell line A427.  Carbonell et al. 
(1985) observed that AcMNPV can enter mouse L929 cells and mediate very low-level 
expression of Escherichia coli chloramphenicol acetyltransferase (CAT) gene from a 
Rous sarcoma virus (RSV) promoter.  In the mid 1990s, two groups demonstrated that 
recombinant AcMNPV containing mammalian cell-active promoters could transduce and 
express foreign genes in mammalian cells.  Recombinant AcMNPV containing a 
cytomegalovirus (CMV) promoter luciferase cassette (Hofmann et al., 1995) or a RSV 
long terminal repeat (LTR) promoter lac-Z cassette (Boyce and Bucher, 1996) were 
observed to cause high levels of reporter gene expression in both primary hepatocytes 
and hepatoma cells.  Shoji et al. (1997) demonstrated that AcMNPV carrying β-
galactosidase (β -gal) under the control of a stronger promoter CAG (cytomegalovirus 
enhancer, chicken β-actin promoter, and rabbit β-globin poly(A) signal) can be used to 
express β -gal in a variety of mammalian cell lines.  Since the discovery that AcMNPV 
can efficiently transduce certain mammalian cell lines, this virus has become a potential 
vector for gene delivery into mammalian cells such as cell-based drug screening 
(Condreay et al., 2006). 
 
1.2.2 Susceptible cell lines. 
Since the study by Volkman and Goldsmith (1983), a variety of non-host cell lines have 
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been evaluated for AcMNPV transduction and the list of cell lines transduced by 
AcMNPV has expanded rapidly (reviewed by Hu, 2006).  A list of cell lines reported to 
be susceptible to AcMNPV transduction is shown in Table 1.1.  Cell lines transduced by 
AcMNPV include human cells (e.g., HeLa, HepG2), non-human primate cells (e.g., COS-
7, CV-1), rabbit cells (e.g., primary hepatocytes), rodent cells (e.g., CHO, BHK), porcine 
cells (e.g., CPK, FS-L3), bovine cells (e.g., MDBK, BT), fish cells (EPC, CHSE-214), 
chicken primary myoblast cells and whole embryonic fibroblast cells.  Efficient 
transduction of various neuroblastomal, nonneuronal cell lines, as well as three human 
neural primary cultures has also been observed (Sarkis et al., 2000).  Moreover, it has 
been demonstrated that mesenchymal stem cells (MSC) from human umbilical cord 
blood and bone marrow, MSC-derived adipogenic, osteogenic, and chondrogenic 
progenitor cells can also be transduced by AcMNPV (Ho et al., 2005; 2006).   
 
1.2.3 Factor that affect transduction efficiency. 
Previous studies showed that transduction efficiencies could range from greater than 90% 
for BHK cells when transduced with a recombinant AcMNPV carrying a CMV-eGFP 
cassette (Chiang et al., 2006) to less than 10 % for NIH-3T3 cells when transducing with 
another recombinant AcMNPV with a CMV-eGFP cassette.  This variability is not only 
cell line dependent, but is also dependent on the transduction temperature, duration, 
media as well as the promoter used to drive the reporter gene.   
 
A. Cell type: 
Early data suggested that AcMNPV can efficiently transduce hepatocytes (e.g., HepG2, 
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Huh-7) from different sources (e.g., human and rabbit).  The efficiencies of hepatocyte 
transformation can be as high as 80% (Wang et al., 2005).  The cellular differentiation 
state may also be a factor influencing transduction efficiency.  Sarkis et al. (2000) 
reported a transduction efficiency of only 30% for undifferentiated human neural 
progenitor cells, but for differentiated neural cells, the efficiency increased to 55%.  
Despite the observation that many kinds of cell lines can be efficiently transduced by 
AcMNPV, certain cell lines of hematopoietic origin, such as U937, K562, Raw264.7 
(Condreay et al., 1999), LCL-cm, and Raji (Cheng et al., 2004), are not transduced 
efficiently.   
 
B. Transduction temperature, duration, and media used: 
Hsu et al. (2004) reported a more efficient transduction protocol than previously used 
protocols.  Recombinant AcMNPV with a CMV-eGFP reporter gene (Bac-CE) had higher 
transduction efficiency at 25°C (78%) than at 37°C (56%) and 4°C (45%).  The 
maximum transduction efficiency of Bac-CE on HeLa cells was reached after 4 hr 
incubation.  Extending the duration of transduction to 8 hr did not significant increase the 
efficiency.  The authors also noted that using PBS as a transduction medium gave the 
highest efficiency for HeLa, HepG2, Huh7, and chondrocytes, while using TMN-FH (Sf9 
insect cell medium) or DMEM (mammalian cell medium) reduced the transduction 
efficiency by approximately 10% and 60%, respectively.  Transient gene expression in 
mammalian cell lines (eg, HeLa, CHO, COS-7, 293, primary human keratinocytes and 
bone marrow fibroblasts) can be enhanced by adding a selective histone deacetylase 
inhibitor Trichostatin A (TSA) or sodium butyrate (Condreay et al., 1999). 
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C. Promoter: 
Most transduction studies have relied on reporter gene cassettes that consist of either GFP 
or luciferase under the control of a mammalian cell active promoter.  The promoters used 
to drive the reporter gene can have a significant impact on the expression level of reporter 
genes in mammalian cells and can impact the observed transduction efficiency.  Shoji et 
al. (1997) compared the expression level of luciferase under the control of either a CAG 
promoter or a CMV reporter.  AcMNPV carrying either a CAG promoter-luciferase or 
CMV promoter-luciferase cassettes both result in high levels of luciferase expression in 
transduced HepG2, Huh-7, and COS-7 cells.  However, tenfold higher luciferase activity 
was observed in HeLa cells transduced with the AcMNPV carrying a CAG promoter 
driven cassette than cells transduced with viruses carrying a CMV promoter driven 
cassette (Shoji et al., 1997).  To date, various promoters have been incorporated into 
AcMNPV to drive reporter gene expression in mammalian cells.  Spenger et al. (2004) 
compared the expression levels of GFP-luciferase fusion protein driven by Simian virus 
40 (SV40), CMV, RSV and a cellular promoter (human ubiquitin C) in CHO, COS-1, and 
HEK293 cells.  Results showed that transgene expression was highest with the CMV and 
RSV promoter, followed by the human ubiquitin C promoter, and lowest with the SV40 
promoter (Spenger et al., 2004).  Recently, it was observed that white spot syndrome 
virus (WSSV) ie1 promoter in the context of a recombinant AcMNPV displayed strong 
promoter activity in both insect and mammalian cells (Gao et al., 2007).   
 
Transcriptional targeting can also be achieved by using cell/tissue-specific promoters.  
Park et al. (2001) reported that recombinant AcMNPV carrying the luciferase gene under 
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the control of human alpha-fetoprotein (AFP) promoter/enhancer expressed luciferase in 
AFP-producing Huh7, Hep3B, and HepG2 cell lines, but not in AFP-nonproducing cell 
lines.  It has also been observed that recombinant AcMNPV carrying a human fms-like 
tyrosine kinase-1 promoter (flt-1-GFP cassette) was able to target GFP expression 
specifically to retinal vasculature in rat eyes in vivo (Luz-Madrigal et al., 2007).   
 
1.2.4 Gene delivery in vivo. 
Use of recombinant AcMNPV as a tool for gene delivery in vitro, as well as in vivo, has 
been studied intensively (reviewd by Hu, 2006).  Gene delivery in vivo using 
recombinant AcMNPV is complicated by the fact that the virus is rapidly inactivated by 
serum complement (Hofmann and Strauss, 1998).  However, protection of AcMNPV-
vectors against complement-mediated inactivation can be achieved by adding 
recombinant soluble complement receptor type 1 (sCR1) to the virus (Hofmann et al., 
1998) or by fusion of human decay-accelerating factor (DAF) to GP64 envelope protein 
to form a DAF-GP64 fusion protein that is displayed on the envelope of AcMNPV (Huser 
et al., 2001).  Vesicular stomatitis virus G protein (VSV-G)-pseudotyped AcMNPV 
increased the transduction efficiency of skeletal muscle, brain and testes in a mouse 
model when compared with the transduction efficiency of control viruses lacking VSV-G 
(Pieroni et al., 2001; Tani et al., 2003).  These results suggest that AcMNPV pseudotyped 
with VSV-G are more resistant to complement-inactivation.  Thus, genetic engineering of 
the viral surface can be an important strategy for improving AcMNPV as a gene delivery 
vector for in vivo applications (Mottershead et al., 1997, 2000; Grabherr et al., 2001; 
Ojala 2001; Oker-Blom et al., 2003; Raty et al., 2004; Riikonen et al., 2005).  A summary 
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of published studies using AcMNPV for in vivo gene delivery is presented in Table 1.2.     
 
1.3 Viral envelope fusion proteins. 
 
1.3.1 Group I NPV envelope fusion protein - GP64. 
Surface glycoproteins of viruses play a very important role in the control and regulation 
of cellular recognition and virus entry.  GP64 is the major envelope protein of AcMNPV 
BV and it is required for binding to cell surface receptors during viral entry by receptor 
mediated endocytosis (Hefferon et al., 1999).  Once the virus is in the endosome, GP64 
also mediates low-pH dependent membrane fusion of the viral envelope with the 
endosome membrane and leads to release of the viral nucleocapsids (NCs) into the 
cytoplasm (Blissard and Wenz, 1992).  GP64 is also essential for virion budding from the 
cell surface during viral egress (Oomens and Blissard, 1999).  Previous studies indicated 
that GP64 is essential for virus propagation both in animals and in tissue culture (Oomen, 
1999; Lung et al., 2002), as well as for the spreading of viral infection from cell to cell 
(Monsma et al., 1996).    
 
To address the role GP64 plays in AcMNPV transduction of mammalian cells, Tani et al. 
(2001) demonstrated that a recombinant AcMNPV with an extra copy of the gp64 gene 
can incorporate about 1.5 times the normal amount of GP64 on the virion surface and 
exhibit 10- to 100-fold more luciferase expression (under the control of the CAG 
promoter) in a variety of mammalian cell lines when compared to control AcMNPV with 
a single copy of the gp64 gene.  Liang et al. (2005) have further demonstrated that while 
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Helicoverpa armigera nucleopolyhedrovirus (HearNPV, a group II NPV, and thus has no 
gp64 gene) does not transduce BHK, HepG2, HeLa, Vero and PK-15 cells.  However, 
HearNPV pseudotyped with AcMNPV GP64 (adding GP64 to the surface of HearNPV 
virions) has the same tropism as AcMNPV and can transduce all of the mammalian cell 
lines tested.  These results suggest that GP64 plays an important role in the interaction of 
AcMNPV with mammalian cells.   
 
1.3.2 Group II NPV envelope fusion protein – F protein. 
A different type of envelope fusion protein (F protein) has been identified in group II 
NPVs - viruses lacking the gp64 gene (IJkel et al., 2000, Pearson et al., 2000).  F proteins 
from group II NPVs such as Spotoptera exigua multiple nucleopolyhedrovirus 
(SeMNPV) and Lymantria dispar multiple nucleopolyhedrovirus (LdMNPV) have low 
pH-dependent fusion activity (IJkel et al., 2000; Pearson et al., 2000).  The SeMNPV F 
protein is synthesized as a proprotein (F0) that is cleaved into two subunits, F1 and F2 
(IJkel et al., 2000).  The cleavage of the precursor protein (F0, 80-kDa) into a small N-
terminal fragment (F2, 21-kDa) and a large C-terminal fragment (F1, 60-kDa) is required 
for activation of the SeMNPV F protein, and is mediated by a furin-like proprotein 
convertase (Westenberg, 2002).  Recently, it was shown that an f-null Helicoverpa 
armigera NPV (HearNPV) could not produce infectious BV when transfected into 
HzAM1 cells, indicating the HearF protein is essential for virus entry and egress (Wang 
et al., 2008).  Previous data showed that F proteins from group II NPVs are functional 
analogs of GP64 and that both the LdMNPV f gene and the SeMNPV f gene can rescue a 
gp64-null AcMNPV and result in production of infectious viral particles (Lung et al., 
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2002).  However, a SeF-null SeMNPV could not be rescued by insertion of the AcMNPV 
gp64 gene, indicating the functional analogy between GP64 and F is not reciprocal 
(Westenberg and Vlak, 2008).  This is likely due to incompatible interactions between the 
fusion proteins and proteins in the heterologous virus or with cellular factors.  The much 
longer cytoplasmic tail domain (CTD) of F protein - in comparison with GP64 - found in 
SeMNPV and other group II NPVs may be required for interaction with nucleocapsids to 
promote budding of group II NPVs, whereas this interaction might not be needed for the 
production of AcMNPV and other group I NPV BVs (Long et al., 2006). 
      
F homologues have also been found in group I NPVs, such as AcMNPV which do have a 
gp64 gene.  The F homologue of AcMNPV (Ac23), is localized to the BV envelope, but 
has no detectable membrane fusion activity.  Ac23 is also dispensable for AcMNPV 
infectivity in both animals and cultured cells (Lung et al., 2003).  However, Ac23 is a 
pathogenicity factor that accelerates host death by approximately 28% or 26 hours (Lung 
et al., 2003), indicating that Ac23 may be involved in other functions that enhance viral 
infection (for details see chapter 3). 
 
1.3.3 Modification of virus envelope protein (pseudotyping). 
The tropism and the transduction efficiency of AcMNPV on non-host cells could 
potentially be modulated by: 1) fusing targeting molecules (peptides or antibodies) to the 
major AcMNPV envelope protein, GP64, and displaying the fused targeting molecule on 
the virion surface (Tami et al., 2000), or 2) displaying glycoproteins from heterologous 
viruses on the AcMNPV envelope, either in place of, or in addition to the endogenous 
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GP64 envelope protein (Barsoum et al., 1997; Mangor et al., 2001; Park et al., 2001; 
Pieroni et al., 2001; Tani et al., 2001; 2003; Lung et al., 2002; Facabene et al., 2004; 
Kitagawa et al., 2005).  Barsoum et al. (1997) reported that VSV-G expressed with the 
polyhedrin promoter is incorporated into AcMNPV budded virion.  These VSV-G-
pseudotyped AcMNPV had a tenfold augmented expression of a lacZ reporter gene 
(under the control of RSV-LTR promoter) in HepG2 cells when compared with AcMNPV 
without VSV-G.  Park et al. (2001) similarly demonstrated that a VSV-G-pseudotyped 
AcMNPV carrying a luciferase reporter gene under the control of human alpha-
fetoprotein (AFP) promoter transduced human hepatoma cells in vitro with fivefold 
greater efficiency than AcMNPV lacking VSV-G.  Both these reports used viruses that 
contained both VSV-G and the endogenous envelope protein GP64.   
 
In addition to VSV-G, F protein from SeMNPV (SeF) and LdMNPV (LdF) have also been 
used to pseudotype gp64null-AcMNPV, in which the endogenous GP64 protein is deleted 
(Mangor et al., 2001; Lung et al., 2002; Kitagawa et al., 2005).  VSV-G, SeF, and LdF 
pseudotyped gp64null-AcMNPV have delayed infection kinetics and have reduced viral 
titer in comparison to wild-type AcMNPV.  Transduction of human 293T and hamster 
BHK cells with the VSV-G-pseudotyped gp64null-AcMNPV showed that expression of 
luciferase reporter gene (under the control of CAG promoter) was dose-dependent and 
the expression level was similar to a control virus without VSV-G (Kitagawa et al., 
2005).  However, expression of a GFP reporter gene under the control of CMV promoter 
were not detectable when BHK-21, LLC-PK1 and H35 cells were transduced with SeF-
pseudotyped gp64null-AcMNPV (Westenberg et al., 2007), suggesting that SeF protein 
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receptors are not present on these mammalian cells.   
 
To date, the cell surface receptor molecule(s) that mediate AcMNPV binding and entry to 
insect and non-insect cells have not been identified.  However, ligand-directed gene 
delivery has been elegantly demonstrated by Kitagawa et al. (2005).  Both CD46 and 
SLAM (receptors for measles virus) can be incorporated onto the surface of gp64null-
AcMNPV, and the small amount of virions generated will specifically transduce BHK 
cells that have been engineered to co-express EdH and EdF - glycoproteins on the 
Edmonston strain of the measles virus - on the cell surface.  Additionally, they 
demonstrated that CD46-pseudotyped gp64null-AcMNPV did not transduce cells co-
expressing IcH and IcF, glycoproteins found on the Ichinose strain of measles virus that 
do not use CD46 as receptors, whereas SLAM-pseudotyped gp64null-AcMNPV could.  
These results indicate that pseudotyped AcMNPV displaying targeting molecules can be 
used for targeted gene delivery.  However, a major drawback is that these pseudotyped 
gp64-null AcMNPV are unable to be amplified due to the lack of an essential GP64 gene, 
and therefore have very limited practical use.     
 
1.4 Summary 
 
There are many properties that make AcMNPV superior to vectors based on mammalian 
viruses for gene delivery into mammalian cells.  AcMNPV replication is restricted to 
certain insect cells, so it is not cytotoxic to mammalian cells; mammals initially do not 
have antibodies against this insect virus; AcMNPV has a large capacity for foreign DNA 
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(estimated capacity for extra DNA is more than 38kb); AcMNPV can enter many 
mammalian cell lines and thus can be used for delivery and expression of genes in these 
mammalian cells.  An introduction to baculovirus and its use in biotechnology related 
application is presented in Chapter 1.  The broad tropism of AcMNPV for a variety of 
cell types is desirable for certain types of in vitro applications, but is undesirable for in 
vivo gene delivery/therapy that requires targeting of specific cell types or tissues.  A new 
method for generating pseudotyped AcMNPV with narrower tropism for mammalian 
cells will be described in Chapter 2.  Ac23 is a fusion (F) protein homologue that has no 
detectable fusion activity, and is dispensable for AcMNPV infectivity in both animals and 
culture cells (Lung et al., 2003).  Previous studies showed that Ac23 is a pathogenicity 
factor that accelerates host death, the mechanism by which this is achieved is not known.  
A study of Ac23 function and how Ac23 contributes to hasten host death will be discussed 
in Chapter 3. 
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Table 1.1 Cells susceptible to transduction by AcMNPV. 
Cell lines Reference 
Human cells 
HepG2 
Boyce and Bucher, 1996; Hofmann et al., 1995; Tani 2001; 
Mahonen et al., 2007; Gao et al., 2007; Shoji et al., 1997; Wang et 
al., 2004 
Huh-7 Boyce and Bucher, 1996; Condreay et al., 1999; Shoji et al., 1997; 
Wang et al., 2004 
HeLa Boyce and Bucher, 1996; Condreay et al., 1999; Chan et al., 2005; 
Ge et al., 2007; Gao et al., 2007; Shoji et al., 1997; Wang et al., 
2004 
Raji Ge et al., 2007 
HR1 Ge et al., 2007 
BJAB Ge et al., 2007 
293 Sollerbrant et al., 2001; Liang et al., 2004; Kitagawa et al., 2005; 
Chan et al., 2005; Kenoutis et al., 2006; Ge et al., 2007; Mahonen 
et al., 2007; Gao et al., 2007 
WI38 Condreay et al., 1999 
MRC5 Palombo et al., 1998; Yap et al., 1998 
MG63 Condreay et al., 1999 
ECV-304 Airenne et al., 2000 
HUVEC Kronschnabl et al., 2002 
PC3 Stanbridge et al., 2003 
KATO-III Shoji et al., 1997 
WISH Changyong et al., 2006 
D98-HR1 Ge et al., 2007 
Osteosarcoma SAOS-2 Condreay et al., 1999; Song et al., 2003 
Pancreatic β cells Ma et al., 2000 
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Keratinocytes Condreay et al., 1999 
Bone marrow fibroblast Condreay et al., 1999 
Primary foreskin fibroblasts Dwarakanath et al., 2001 
Primary neural cells Sarkis et al., 2000 
SMMC-7721(hepatoma) Changyong et al., 2006 
Nonhuman primate cells 
COS-7 
Condreay et al., 1999; Liang et al., 2004; Shoji et al., 1997 
Vero Poomputsa et al., 2003; Airenne, et al., 2000; Changyong et al., 
2006; Gao et al., 2007 
CV-1 Tani et al., 2001 
B95-8 Ge et al., 2007 
Rodent cells 
CHO 
Condreay et al., 1999; Hu et al., 2003a; Chan et al., 2005 
BHK Condreay et al., 1999; Hu et al., 2003a; Tani et al., 2001; Liang et 
al., 2004; Kitagawa et al., 2005; Chan et al., 2005; Changyong et 
al., 2006; Chiang et al., 2006; Westenberg et al., 2007; Gao et al., 
2007; Wang et al., 2004 
RGM1 Shoji et al., 1997 
PC12 Shoji et al., 1997 
N2a Sarkis et al., 2000 
L929 Airenne et al., 2000; Cheng et al., 2004; Changyong et al., 2006 
H35 Westenberg et al., 2007 
Primary mouse kidney cells 
(MKC) 
Liang et al., 2004 
Mouse Pancreatic β cells Ma et al., 2000 
Rat hepatic stellate cells Gao et al., 2002 
Primaryosteoblast and osteoclast Boyce and Bucher, 1996 
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Primary rat hepatocytes Tani et al., 2003 
Rat articular chondrocyte Ho et al., 2004; Wang et al., 2004 
Rabbit cells 
Rabbit aortic smooth muscle 
Raty et al., 2004; Mahonen et al., 2007 
RK13 Nakamichi et al., 2002 
Primary hepatocytes Munger and Roizman, 2001 
Bovine cells 
MDBK 
Aoki et a., 1999; Airenne, K.J. 2000 
BT Aoki et al., 1999 
Porcine cells 
CPK 
Aoki et al., 1999; Shoji et al., 1997 
FS-L3 Shoji et al., 1997 
PK-15 Aoki et al., 1999; Airenne, et al., 2000; Liang et al., 2004; Gao et 
al., 2007 
LLC-PK1 Westenberg et al., 2007 
Fish cells 
EPC 
Leisy et al., 2003 
CHES-214 Leisy et al., 2003 
CHH-1 Leisy et al., 2003 
Embryo Wagle and Jesuthasan, 2003 
Avian 
chicken primary myoblast cells 
Ping et al., 2006 
Embryonic fibroblast cells Ping et al., 2006 
Primary liver cells Song et al., 2006 
Primary kidney cells Song et al., 2006 
Primary lung cells Song et al., 2006 
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Table 1.2 In vivo studies of AcMNPV-mediated transduction. 
Envelope protein Trans/Reporter 
gene 
Target organ Delivery 
method 
Reference 
GP64 
 
GFP 
Rodent brain Direct injection 
into brain 
Sarkis et al., 2000 
lacZ 
Rat brain Direct injection 
into brain 
Lehtolainen et al., 
2002 
GFP 
Rat eye Direct injection 
into vitreous 
body 
Luz-Madrigal et al., 
2007 
luciferase 
Rat brain Stereotaxic 
injection into the 
rat striatum 
Li et al., 2004 
lacZ 
Mouse liver Portal vein 
infusion 
Hoare et al., 2005 
lacZ 
Rabbit carotid 
arteries 
A silastic collar 
placed around 
rabbit carotid 
arteries 
Airenne et al., 2000 
Pseudorabies virus 
glycoprotein gB 
Muscle, nose Direct injection 
into muscle 
Aoki et al., 1999 
GP64 + soluble 
DAF* 
human factor IX 
(hFIX) 
Rat liver Direct injection 
into liver 
Huser et al., 2001 
GP64 + VSV-G 
lacZ 
Mouse skeletal 
muscle 
Direct injection 
into mouse 
quadriceps 
Pieroni et al., 2001 
lacZ 
Mouse striatum Direct injection 
into the mouse 
striatum 
Kobayashi et al., 
2006 
GFP 
Mouse brain, 
testes 
Direct injection 
into mouse brain 
Tani et al., 2003 
*DAF: human decay-accelerating factor 
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Chapter 2 – Pseudotyping gp64null-AcMNPV with the F protein from SeMNPV 
diminishes transduction efficiency into non-insect cells. 
 
2.1 Introduction. 
 
Baculovirus are insect viruses with many biotechnological and biomedical applications.  
Recently it was discovered that the type baculovirus, Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV), can efficiently enter a broad range of mammalian cell 
lines including human HepG2 (Tani et al., 2001), monkey VERO (Airenne et al., 2000), 
murine BHK-21 (Condreay et al., 1999), porcine PK-15 (Airenne et al., 2000) as well as 
primary cells such as human primary hepatocytes (Hofmann et al., 1995), rat primary 
hepatocytes (Boyce and Bucher, 1996), chicken primary myoblast cells and whole 
embryonic fibroblast cells (Ping et al., 2006).  Upon entry into non-insect cells AcMNPV 
does not replicate, and appear to cause little or no cytopathic effect.  Thus, AcMNPV is a 
useful tool for delivering genes into mammalian cell lines for applications such as cell-
based drug screening (reviewed by Kost et al., 2005).  The use of AcMNPV as a vector 
for delivering genes into mammalian cells in vivo, for applications such as gene therapy 
or as a vector for vaccine delivery is also being explored (reviewed by van Oers, 2006).  
Advantages of using AcMNPV as a vector for gene delivery into mammalian cells in vivo 
include: 1) a large capacity for foreign DNA; the viral genome can be easily engineered 
and propagated with an insertion of more than 38kb containing multiple genes 
(Cheshenko et al., 2001); 2) a better biosafety profile since AcMNPV does not replicate 
or express most of its genes in mammalian cells, and thus in comparison with other viral 
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vectors (e.g., Retrovirus, Lentivirus, Adenovirus) that could cause serious toxicity or 
induce oncogenesis in human cells, there is little observable cytopathic effect (reviewed 
by Hu, 2006); 3) antibodies against this insect virus are initially absent in humans (Van 
Oers, 2006).  One of the obstacles for AcMNPV-mediated in vivo gene delivery is 
complement-mediated inactivation of AcMNPV (Hofmann and Strauss, 1998).  
Protection of AcMNPV-vectors from complement-mediated inactivation have been 
observed with recombinant soluble complement receptor type 1 (sCR1, Hofmann et al., 
1998), and also by incorporation of decay-accelerating factor (DAF) into the AcMNPV 
envelope (Huser et al., 2001).  Studies also showed that a recombinant AcMNPV 
displaying or pseudotyped with the envelope protein of a heterologous virus, vesicular 
stomatitis virus G protein (VSV-G) could efficiently transduce cells in the mouse skeletal 
muscle, cerebral cortex and testis in vivo (Pieroni et al., 2001; Tani et al. 2003), 
suggesting that AcMNPV modified with VSV-G protein might have the ability to resist 
complement inactivation.  Thus, modification of viral surface proteins is a potentially 
useful approach for improving the use of AcMNPV for in vitro and in vivo gene delivery 
(Grabherra, 2001; Mottershead, et al., 1997, 2000; Ojala, 2001; Oker-Blom, et al., 2003; 
Raty, et al., 2004; Riikonen, et al., 2005).  
 
The ability of AcMNPV to enter many types of mammalian cells has been a desirable trait 
for its use in applications such as cell-based drug screening assays.  However, this broad 
tropism may be less desirable for in vivo applications that require or benefit from gene 
delivery into specific cell types.  Virus binding and entry into non-target cell types could 
dilute the input virus, decrease the efficacy, and have negative consequences on 
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unintended target cells.  Therefore, finding ways to generate viral vectors that can target 
specific cell types is an important step in advancing the use of AcMNPV for in vivo 
applications.  AcMNPV budded virus (BV) enter host insect cells via endocytosis, 
mediated by the major BV envelope protein GP64 (Blissard and Wenz, 1992).  Previous 
studies have shown that phospholipids on the cell surface might be important docking 
spots for the GP64 protein (Tani et al., 2001), but the receptor for AcMNPV in insect 
cells has not been identified.  Viral tropism could be modulated by altering proteins on 
the surface of the virion (pseudotyping).  Pseudotyping AcMNPV with VSV-G has been 
done in the presence or absence of the endogenous envelope protein GP64 (Barsoum et 
al., 1997; Mangor et al., 2001).  Kitagawa et al. (2005) showed that expression of the 
luciferase reporter gene in 293T cells transduced with VSV-G pseudotyped gp64null-
AcMNPV was inhibited by antibodies against VSV-G.  This result suggests that VSV-G 
pseudotyped gp64null AcMNPV-mediated gene expression in the 293T cells is dependent 
on interactions mediated by VSV-G proteins on the virion.  Pseudotyping of AcMNPV by 
displaying a targeting molecule on the surface of the virion has been shown to target viral 
entry into specific cell types.  Kitagawa et al. (2005) elegantly showed that gp64null-
AcMNPV pseudotyped with CD46 or SLAM (receptors of measles virus) are specifically 
targeted to cells expressing measles virus envelope glycoproteins.  However, gp64 is an 
essential gene that is required for progeny virus production (Oomens et al., 1999; Lung et 
al., 2002).  Deletion of gp64 results in extremely low yield of gp64-minus viruses that 
can not be propagated and amplified, thus limiting the practical use of these types of 
viruses.  Previous results have shown that envelope fusion proteins from heterologous 
viruses such as SeMNPV or LdMNPV (SeF and LdF) can also functionally substitute for 
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GP64 and result in the production of significantly higher amounts of gp64-minus progeny 
viruses that are easily propagated (Lung et al., 2002).  The gp64-minus AcMNPV viruses 
display SeF protein on its surface and are called SeF-pseudotyped gp64-null AcMNPV 
(Lung et al., 2002).  Several lines of evidence suggest that SeF will likely not confer SeF-
pseudotyped gp64null-AcMNPV with the ability to transduce mammalian cells 
efficiently.   To determine whether AcMNPV tropism for non-insect cells can be 
narrowed by pseudotyping gp64-null AcMNPV with SeF, a recombinant SeF-
pseudotyped gp64-null AcMNPV virus expressing the humanized renilla green 
fluorescent protein (hrGFP) under the control of a cytomegalovirus (CMV) promoter was 
generated.  The transduction efficiency of the SeF-pseudotyped gp64-null AcMNPV virus 
was determined on 15 cell lines derived from human, monkey, murine, porcine, feline, 
canine, bovine, ovine, avian, and fish species.  Here, I show that SeF-pseudotyped 
gp64null AcMNPV has very low or no detectable reporter gene expression in non-insect 
cells, suggesting this pseudotyped virus could potentially serve as a platform for 
generating “designer viruses” for targeted gene delivery in vivo. 
 
2.2 Materials and Methods 
 
2.2.1 Cloning and plasmid construction. 
2.2.1.1 PCR and primers. 
All PCRs were performed with GeneAmp® PCR system 9700 thermocycler (Applied 
Biosystems) and PhusionTM High-Fidelity DNA polymerase (Fermentas) according to the 
manufacturer’s instructions.  The typical reaction volume was 50 µL (10µL Phusion HF 
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buffer (5X), 1µL dNTPs (10mM), 5 µL primers (5 µM), 1 µL  DNA template(10ng total), 
0.5 µL Phusion DNA polymerase, and 27.5 µL H2O) and a typical cycle program is 1 
cycle at 98°C (30 sec), followed by 27 cycles of 98°C (10 sec), 50-60°C (30 sec), 72°C 
(30 sec/1 kb), and a final extension of 7 min at 72°C.  The primers used for PCR 
amplification are summarized in Table 2.1. 
 
2.2.1.2 Cloning of reporter genes for detection of expression in non-insect cells. 
The open reading frames (ORF) of luciferase (Luc) and hrGFP were amplified using the 
plasmid pCMV-Luc (Dr. Yu-Chan Chao, Academia Sinica, Taiwan) and plasmid pIRES-
hrGFP-1a (Stratagene) as template, respectively.  Primers used to amplify Luc (P5’SacI-
Luc and P3’Luc-XhoI) were designed to generate XhoI and SacI restriction sites upstream 
and downstream of the Luc ORF, respectively.  Primers for hrGFP amplification (P5’-
SacI-hrGFP and P3’hrGFP-SexAI) were designed to generate SacI and SexAI restriction 
sites upstream and downstream of the hrGFP ORF, respectively. 
 
The PCR products were digested with restriction enzymes and cloned downstream of the 
CMV promoter in the plasmid pIRES-hrGFP-1a ∆ 3x FLAG-IRES-hrGFP.  The resulting 
constructs were named pCMV-Luc (KY1) and pCMV-hrGFP (KY4).  Luc and hrGFP 
ORF under the control of a CMV promoter were re-amplified by PCR using KY1 and 
KY4 as templates and cloned into a shuttle vector pFBDM (Berger et al., 2004), which 
contains a Tn7 transposon harbouring baculovirus promoter upstream of multiple cloning 
sites, to generate pFB/CMV-Luc (KY3) and pFB/CMV-hrGFP (KY5), respectively.  
Primers P5’NruI-CMV and P3’Luc-XbaI were used to amplify the CMV-Luc fragment, 
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while primers P5’NruI-CMV and P3’-hrGFP-XbaI were used to amplify the CMV-hrGFP 
fragment. 
 
2.2.1.3 Cloning of envelope protein genes and insect cell reporter genes. 
A total of three PCR amplified fragments containing a β-glucuronidase (GUS) reporter 
gene (under the control of the P6.9 promoter) with or without genes encoding the 
envelope proteins GP64 and SeF, under the control of the gp64 promoter were amplified.  
Plasmids p∆FB/gus(R)Acgp64-10dATG (Lung et al., 2002) were used as the template for 
the gp64 containing fragment (P6.9-GUS-Pgp64-GP64) and p∆FB/gus(R)Se8-32+stop-
ATG (Lung et al., 2002) were used as template for both the SeF containing fragment 
(P6.9-GUS-Pgp64-SeF) and the fragment without envelope protein genes (P6.9-GUS).  
P6.9-GUS was amplified using primers P5’-AvrII-P6.9 and P3’gus-RsrII-I-Scel-Cfr9I.  
P6.9-GUS-Pgp64-SeF was amplified using primers P5’-AvrII-P6.9 and P3’SeF-RsrII-I-
Scel-Cfr9I.  P6.9-GUS-Pgp64-GP64 was amplified using primers P5’-AvrII-P6.9 and 
P3’GP64-RsrII-I-Scel-Cfr9I.  PCR products were cloned into pJET1/blunt cloning vector 
according to the manufacturer’s instructions (Fermentas) to generate pJET/P6.9-GUS 
(KY7), pJET/P6.9-GUS-Pgp64-SeF (KY8), and pJET/P6.9-GUS-Pgp64-GP64 (KY9).  
Each of the three vectors were double digested with AvrII and Cfr9I, and gene fragments 
containing the envelope protein gene and/or the GUS gene were gel purified and cloned 
individually into the two shuttle vectors KY3 and KY5.  Thus, a total of six shuttle vector 
constructs with different combination of genes were generated: p∆FB/P6.9-GUS-CMV-
Luc (KY13), p∆FB/P6.9-GUS-Pgp64-SeF-CMV-Luc (KY14), p∆FB/P6.9-GUS-Pgp64-
GP64-CMV-Luc (KY15), p∆FB/P6.9-GUS-CMV-hrGFP (KY16), p∆FB/P6.9-GUS-
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Pgp64-SeF-CMV-hrGFP (KY17), p∆FB/P6.9-GUS-Pgp64-GP64-CMV-hrGFP (KY18).  
A summary of the plasmid constructs generated for this work is presented in Table 2.2. 
 
2.2.2 Cell lines and media. 
Baby hamster kidney (BHK-21), human hepatocellular carcinoma (Hep G2), chicken 
UMNSAH/DF-1, and chicken SL-29 cells were obtained from American Type Culture 
Collection (ATCC).  Swine Testicle (ST), Mouse McCOY, African Green monkey Kidney 
(VERO), Fish Stripped Snake-Head (SSN-1), Fish Gonad Rainbow trout (RTG-2), and 
canine MDCK cells were obtained from Dr. John Robinson (Animal Health Center, 
Abbotsford, BC).  Bovine MDBK, fish EPC, fish CHSE-214, porcine PK-15, and ovine 
SCP cells were from the Canadian Food Inspection Agency, Lethbridge Laboratory, 
Lethbridge, AB.  Sf9 cells were cultured in TMN-FH (Grace’s media (Sigma) 
supplemented with 10% v/v FBS, 3.7g/ml Lactalbumin hydrosylate, 3.7g/ml Yeastolate, 
0.35g/ml Sodium bicarbonate, pH 6.2) at 27°C.  All mammalian cell lines were kept in 
5% CO2, at 37°C; and chicken UMNSAH/DF-1 cells were kept in 5% CO2 at 39°C.  
HepG2, PK-15 and BHK-21 cells were maintained in Minimum Essential Medium 
(MEM, Hyclone) supplemented with 1% (v/v) sodium pyruvate and 10% (v/v) defined 
Fetal Bovine Serum (DFBS, Hyclone) at 37°C, 5% CO2.  CHSE-214 and EPC cells were 
mantained in MEM supplemented with 10% (v/v) characterized FBS (CFBS, Hyclone) at 
room temperature.  ST, McCOY, SSN-1, and RTG-2 cells were cultivated in Eagle’s 
MEM (Sigma) with 10% DFBS.  ST was also supplemented with 1% non-essential amino 
acid (Sigma).  VERO cells were maintained in Eagle’s Basal Medium (Sigma) 
supplemented with 5% DFBS, MDCK cells were maintained in Alpha MEM 
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supplemented with 10% DFBS, and UMNSAH/DF-1 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, ATCC) supplemented with 10% DFBS.  
Cells, media and culture conditions are summarized in Table 2.3. 
 
2.2.3 Generation of recombinant virus. 
Recombinant viruses were generated as described in the Bac-to- Bac ® baculovirus 
Expression System manual (Invitrogen).  Six recombinant shuttle vectors with the Luc or 
hrGFP reporter gene (KY13-KY18) were transformed into DH10gp64nullBac electro-
competent E. coli cells harboring the gp64null bacmid, gp64null-pMON14272 (Lung et 
al., 2002) and the helper plasmid pMON7124 which contains the Tn7 transposase gene 
necessary for Tn7-mediated transposition of genes on the shuttle plasmid onto the 
bacmid.  The resulting recombinant bacmids were named bgp64nullAcBac/∆FBgus- 
CMV-hrGFP, and bgp64nullAcBac/∆FBgus-CMV-Luc (no envelope protein gene 
transposition); bgp64nullAcBac/∆FBgus-SeF-CMV-hrGFP and bgp64nullAcBac/∆FBgus- 
SeF-CMV-Luc (SeF gene transposition); bgp64nullAcBac/∆FBgus-GP64-CMV-hrGFP 
and bgp64nullAcBac/∆FBgus-GP64-CMV-Luc (gp64 gene transposition), respectively.  
Four of the six shuttle vectors (KY 13, 14, 16 and 17) were also transformed into E. coli 
DH10Bac electrocompetent cells harboring the helper plasmid, pMON7124 and the 
AcMNPV bacmid pMON14272 with the gp64 envelope protein gene intact.  The 
resulting recombinant bacmids were called bAcBac/∆FBgus-CMV-hrGFP and bAcBac/ 
∆FBgus-CMV-Luc (with one copy of the gp64 gene); bAcBac/∆FBgus-SeF-CMV-hrGFP 
and bAcBac/∆FBgus-SeF-CMV-hrGFP (with one copy of the gp64 gene and one copy of 
the SeF gene).  A schematic representation of all recombinant bacmid constructs are 
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shown in Fig 2.2.  The recombinant bacmids were confirmed by PCR amplification of the 
envelope protein genes and the reporter genes (see section 2.4).  The following five of the 
ten recombinant bacmids carrying hrGFP reporter genes were selected for further 
research: bgp64nullAcBac/∆FBgus-CMV-hrGFP, bgp64nullAcBac/∆FBgus-SeF- 
CMV-hrGFP, bgp64nullAcBac/∆FBgus-GP64-CMV-hrGFP, and bAcBac/∆FBgus- 
CMV-hrGFP, bAcBac/∆FBgus-SeF-CMV-hrGFP.  Three independent clones were initially 
selected for each construct, amplified overnight in 5 ml LB broth (10% w/v Tryptone, 
0.5% w/v Yeast extract, 1.0% NaCl, pH 7.0) containing kanamycin (50 µg/ml), 
gentamycin (7 µg/ml) and tetracycline (10 µg/ml).  Bacmid DNA isolation was 
performed according to the Bac-to-Bac® manual (Invitrogen), and 5µL of the bacmid 
DNA was transfected into Sf9 cells using lipofectin (Campbell, 1995).  A mixture of 
20µL of lipofectin (L-alpha-phosphatidylethanolamine, dioleoyl (DOPE): 
Dimethyldioctadecyl-ammonium bromide (DDAB) at a 2:1 molar ratio), 200µL of 
Grace’s media (Sigma), and 5µL of bacmid DNA were incubated at room temperature for 
1 hour.  After the 1 hour incubation, 800µL of fresh Grace’s media were added to the 
mixture and 1ml of the transfection solution were then added to 9 x 105 Sf9 cells that 
have been washed once with PBS.  The transfected cells were incubated at 27°C for 4 hr, 
the transfection media was replaced with 2ml of fresh TMN-FH media, and incubated at 
27 °C for another 72 hours.  At 3 days post transfection (dpt, 5 dpt for bAcBac/∆FBgus-
SeF-CMV-hrGFP), the culture medium was harvested, centrifuged at 500 g for 5 min, and 
the supernatant was stored at 4°C, protected from light as the P1 virus stock.  The viral 
titer of P1 virus stocks was determined by the end point dilution method described in 
O’Reilly et al. (1992).  A single clone for each of the five viruses was chosen for analysis 
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and further amplified by infecting two T150 flasks of Sf9 cells (1.68 x 107cells/flask) at a 
multiplicity of infection (moi) of 0.1.  At 3 dpi (5 days for bAcBac/∆FBgus-SeF-CMV-
hrGFP), medium from the infected cells was harvested and centrifuged at 500 x g for 5 
min, the resulting supernatant was stored at 4°C protected from light as the P2 virus 
stock.  P3 virus stocks were amplified from P2 virus stocks as described for the 
amplification of the P2 stock for vAcSeF-CMV-hrGFP, vgp64nullAcGP64-CMV-hrGFP, and vAcCMV-
hrGFP, respectively.  The vgp64nullAcSeF-CMV-hrGFP virus was amplified using ten T175 flasks 
(1.4 x 107 Sf9 cells/ flask).  At 3 dpi (5 dpi for vgp64nullAcSeF-CMV-hrGFP), the culture 
medium was harvested, and centrifuged at 500 x g for 5 min.  The resulting supernatant 
was centrifuged at 45,000 g for 1 hour at 4°C to concentrate the virus.  The viral pellet 
was resuspended in 10 ml of the clarified supernatant plus 10 ml PBS. The resuspended 
concentrated virus were filtered through a 0.2 µm MFS filter (Advantec MFS), titered and 
store at 4°C protected from light. 
 
2.2.4 Confirmation of constructs and virus by PCR and Western blot analysis. 
Plasmids and shuttle vectors were all confirmed by PCR using gene specific primers as 
well as by restriction enzyme digestion.  Recombinant bacmid DNAs were confirmed by 
three sets of primers: 1) PCR using the M13 forward and M13 reverse primers outside of 
Tn7-attachment sites was performed to ensure the Tn7-mediated transposition had taken 
place, and to rule out the presence of bacmids without an Tn7 insert; 2) PCR using the 
M13 forward primer and a forward primer specific for either GUS or gp64 or SeF were 
used to confirm the transposition of the correct envelope protein gene; 3) PCR using the 
M13 reverse primer and a forward primer specific to either hrGFP or Luciferase were 
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performed to confirm the presence of the correct reporter gene.  All recombinant viruses 
were also confirmed by extracting DNA from virus infected Sf9 cells at 3 dpi using 
DNeasy Tissue Kit (Qiagen), and performing a PCR analysis using primer pairs specific 
to GUS, SeF and gp64 genes.  For Western blot confirmation of envelope proteins, 9 x 
109 Sf9 cells were infected at a moi of 1, washed once in PBS, resuspended in 110 µL 
PBS and 110 µL Laemmli buffer (Bio-Rad) supplemented with 5% β-mercaptoethanol 
and boiled for 10 min.  Samples were electrophoresed in sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) at 150V for 1 hr, and transfered onto 
Immobilon-P membrane (Millipore) for 30 min using semi-dry transfer (Bio-Rad) at 15V.  
Membranes were blocked overnight in TBST (10mM Tris, 150mM NaCl, 0.05% v/v 
Tween-20) plus 4% skim milk at 4°C.  Membranes were then incubated with either 
mouse anti-GP64 antibody (AcV5, gift of Dr. Gary Blissard, Boyce Thompson Institute) 
or a chicken anti-SeF1 antibody (Westenberg et al., 2002) at 1:1000 dilution for 1 hour at 
room temperature.  After washing twice with TBST, membranes were incubated in AP- 
conjugated anti-mouse or anti-chicken 2° antibody (Medicorp) at 1:5000 dilution for 1 
hour at room temperature.  Blots were then washed three times with TBST and three 
times with TBS (5 min each).  Color development using 5-bromo,4-chloro,3-
indolylphosphate (BCIP)/nitroblue tetrazolium (NBT) substrate was performed as per 
manufacturer’s protocol (Bio-Rad). 
 
2.2.5 Transduction. 
For transduction experiments, most cell lines were seeded into 24-well plates at a density 
of 5 x 104 cells/well and allowed to attach overnight.  Smaller cells like EPC and SSN-1 
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were seeded at a density of 1 x 105 cells/well and bigger cells like PK-15 and BHK-21 
were seeded at a density of 5 x 103 cells/well.  Cells were then washed once with PBS, 
and each virus was added to duplicate wells at a moi of 500 and brought to a final volume 
of 200µl with PBS plus 5% (v/v) FBS.  Cells were placed on an orbital shaker (Nutator, 
Becton Dickinson) for 6 hours at room temperature.  Two ml of fresh TMN-FH growth 
medium were added to the cells and incubated for 24 hr at 39°C (UMNSAH/DF-1), 37°C 
(HepG2, BHK-21, VERO, McCOY, FKC, PK-15, MDBK, SCP, MDCK, SL-29, ST) or 
room temperature (EPC, CHES-214, RTG-2, SSN-1).  After 24 hours of incubation, cells 
were fixed in 10% formalin for 3 min, washed once with PBS, and stained with 4’,6’-
diamidino-2-phenylindole dihydrochloride (DAPI, 300nM in PBS, Invitrogen) for 5 min.  
Cells were then washed twice with PBS, and photographed with a fluorescence 
microscope (CKX41, Olympus).  Image-Pro 6.2 was used to determine the number of 
DAPI-stained nuclei in the micrographs, and the transduction efficiency was determined 
by calculating the percentage of DAPI-stained cells that were also GFP positive.  To 
determine the infectivity of the inoculum, Sf9 cells (2.25 x 105 cells/ well) were infected 
with post-transduction inoculum, and at 3 dpi, 2 µL of X-glucuronide (X-gluc, 20mg/ml 
in DMSO, Biovectra) were added to each well to detect the presence of GUS activity. 
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Table 2.1 PCR primers used in this study. 
Primer name Primers sequence 
P5’SacI-Luc 5’GGCCGAGCTCATGAAGCTTGGCATTCCGG-3’ 
P3’Luc-XhoI 5’-GGCCCTCGAGTTACAATTTGGACTTTCCGCCC-3’ 
P5’-SacI-hrGFP 5’-GGCCGAGCTCATGGTGAGCAAGCAGATCC-3’ 
P3’hrGFP-SexAI 5’-GGCCACCAGGTTTACACCCACTCGTGCAG-3’ 
P5’NruI-CMV 5’-GGCCTCGCGAGGCGACCGCCCAGCGAC-3’ 
P3’Luc-XbaI 5’GGCCTCTAGACGAGTTACAATTTGGACTTT-3’ 
P3’-hrGFP-XbaI 5’GGCCTCTAGATTACACCCACTCGTGCAG-3’ 
P5’-AvrII-P6.9 5’-AATACCTAGGCTTACGATCTGTCGACGAAATTC-3’ 
P3’gus-RsrII-I-Scel-Cfr9I 5’-ATATCCCGGGCGGACCGATTACCCTGTTATCCCTATCATTGTTTGCCTCCCTGCTG-3’ 
P3’SeF-RsrII-I-Scel-Cfr9I 5’-ATATCCCGGGCGGACCGATTACCCTGTTATCCCTATCACATGGGTTCCATTTCCATG-3’ 
P3’GP64-RsrII-I-Scel-Cfr9I 5’-ATATCCCGGGCGGACCGATTACCCTGTTATCCCTACTTAATATTGTCTATTACGGTTTC-3’ 
M13 forward 5’-GTTTTCCCAGTCACGAC-3’ 
M13 reverse 5’-CAGGAAACAGCTATGAC-3’ 
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Table 2.2 Plasmid constructs generated in this study. 
Construct 
Name 
Vector 
backbone 
Inserted genes and flanking 
restriction enzyme sites 
E. coli strain 
transformed 
KY1 pIRES-hrGFP-1a SacI-Luc-XhoI DH10B 
KY3 pFBDM NruI-CMV-Luc-XbaI DH10B 
KY4 pIRES-hrGFP-1a SacI-hrGFP-SexAI DH10B 
KY5 pFBDM NruI-CMV-hrGFP-XbaI DH10B 
KY7 pJET1/blunt AvrII-P6.9-GUS-RsrII-I-Scel-Cfr9I DH5α 
KY8 pJET1/blunt AvrII-P6.9-GUS-Pgp64-SeF-RsrII-I-Scel-Cfr9I DH5α 
KY9 pJET1/blunt AvrII-P6.9-GUS-Pgp64-GP64-RsrII-I-Scel-Cfr9I DH5α 
KY13 KY3 AvrII-P6.9-GUS-RsrII-I-Scel-Cfr9I DH10B 
KY14 KY3 AvrII-P6.9-GUS-Pgp64-SeF-RsrII-I-Scel-Cfr9I DH10B 
KY15 KY3 AvrII-P6.9-GUS-Pgp64-GP64-RsrII-I-Scel-Cfr9I DH10B 
KY16 KY5 AvrII-P6.9-GUS-RsrII-I-Scel-Cfr9I DH10B 
KY17 KY5 AvrII-P6.9-GUS-Pgp64-SeF-RsrII-I-Scel-Cfr9I DH10B 
KY18 KY5 AvrII-P6.9-GUS-Pgp64-GP64-RsrII-I-Scel-Cfr9I DH10B 
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Table 2.3 Animal cell lines and culturing conditions. 
Cell line Source Media Supplements Temp
. 
Sf9 Insect TMN-FH 10% CFBS* 27°C 
HepG2 Human MEM** 1% sodium pyruvate, 10% DFBS*** 37°C 
BHK-21 Murine MEM 1% sodium pyruvate, 10% DFBS 37°C 
PK-15 Porcine MEM 1% sodium pyruvate, 10% DFBS 37°C 
CHSE-214 Fish MEM 10% CFBS RT 
EPC Fish MEM 10% CFBS RT 
McCOY Mouse Eagle’s MEM 10% DFBS 37°C 
FKC Feline Eagle’s MEM 10% DFBS 37°C 
SSN-1 Fish Eagle’s MEM 10% DFBS RT 
RTG-2 Fish Eagle’s MEM 10% DFBS RT 
ST Porcine Eagle’s MEM 1% non-essential amino acid, 10% DFBS 37°C 
VERO Monkey Eagle’s Basal 
Medium 
5% DFBS 37°C 
MDCK Canine Alpha MEM 10% FDBS 37°C 
MDBK Bovine MEM 5% Horse Serum 37°C 
SCP Sheep MEM 5% Horse Serum 37°C 
UMNSAH/DF-1 Chicken DMEM 10% DFBS 39°C 
  *CFBS: characterized fetal bovine serum 
 **MEM: Minimum essential medium 
***DFBS: Defined fetal bovine serum 
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2.3 Results 
2.3.1 Generation of shuttle vectors carrying reporter and envelope protein genes. 
A total of 13 plasmids (KY1, 3, 4, 5, 7-9, 13-18) carrying different combinations of 
mammalian reporter genes and baculovirus envelope protein genes were generated in this 
study (Table 2.2, Fig. 2.1).  Six shuttle vectors (KY13~18) were used to insert the 
reporter genes and envelope protein genes into the cloned AcMNPV genome (bacmid) by 
Tn7-mediated transposition.  All six shuttle vectors were used to insert genes into a 
gp64null-AcMNPV bacmid (gp64null-pMON14272, Lung et al., 2002) in which the gene 
encoding the major BV envelope protein was deleted.  Four shuttle vectors (KY13, 14, 
16, and 17) were used to insert genes into the AcMNPV bacmid (pMON14272) in which 
the gp64 gene was intact.  A schematic diagram of the bacmid constructs generated is 
illustrated in Fig 2.2.  A total of ten recombinant bacmids, five with hrGFP reporter gene, 
and five with a Luc reporter gene were generated (Fig 2.2): bgp64nullAcBac/∆FBgus-
CMV-hrGFP, and bgp64nullAcBac/∆FBgus-CMV-Luc (no envelope protein gene 
transposition); bgp64nullAcBac/∆FBgus-SeF-CMV-hrGFP and bgp64nullAcBac/∆FBgus-
SeF-CMV-Luc (with SeF gene transposition); bgp64nullAcBac/∆FBgus-GP64-CMV- 
hrGFP and bgp64nullAcBac/∆FBgus-GP64-CMV-Luc (with gp64 gene transposition); 
bAcBac/∆FBgus-CMV-hrGFP and bAcBac/∆FBgus-CMV-Luc (with endogenous gp64 
gene); bAcBac/∆FBgus-SeF-CMV-hrGFP and bAcBac/∆FBgus-SeF-CMV-Luc (with both 
the endogenous gp64 gene and SeF gene transposition).  The bacmids were confirmed by 
PCR using primer pairs specific for the reporter genes and the envelope protein genes 
(Fig. 2.3).  The five recombinant bacmids with the hrGFP reporter gene were transfected 
into Sf9 cells to generate recombinant viruses that either had the endogenous envelope  
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Fig 2.1 Linear maps of shuttle vectors carrying reporter genes and/or envelope genes 
generated for this study. KY3, 5, 13-18 were constructed from a shuttle vector, pFBDM, 
where the gene of interest was inserted in between the Tn7-transposition sites. KY7-9 
were constructed from a PCR cloning vector, pJET1/blunt, where the PCR products can 
be directly cloned into the multiple cloning site. GmR= Gentamycin resistance gene, 
AmpR= Ampicilline resistance gene, Tn7R (L) = Tn7-attachment right (left) site. 
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Fig 2.2 Schematic diagram of the ten bacmid constructs generated in this study.  The 
gp64 gene was replaced with the CAT gene in gp64null-Acbacmid (A, C, D), while the 
gp64 gene is intact in Acbacmid (B, C). Insertion of hrGFP mammalian reporter genes (or 
alternatively, the Luc reporter gene) and GUS insect reporter genes into the polyhedrin 
locus was performed by Tn7-mediated transposition for all bacmid constructs. A gp64 
envelope protein gene (C) and a SeF envelope protein gene (D, E), both under the control 
of Pgp64 was inserted downstream of the GUS gene. PCR analysis were performed to 
ensure the transposition had taken place and also to rule out the presence of bacmids 
without any inserts. The relative position of the PCR primers used for bacmid 
confirmation is indicated (dashed arrows). 
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Fig 2.3 Confirmation of bacmid DNA by PCR analysis using: A) a M13 reverse primer 
and a hrGFP forward primer (lanes 1-5), or a M13 reverse primer and a Luciferase 
forward primer (lanes 6-10); B) a M13 forward primer and a GUS forward primer (lanes 
1, 2, 6, 7), a M13 forward primer and a gp64 forward primer (lanes 3, 8), a M13 forward 
primer and a SeF forward primer (lanes 4, 5, 9, 10); and C) a M13 forward and a M13 
reverse primer. All PCR reactions gave the expected amplicon size and none of the 
bacmid-preparations produced a 300 bp amplicon with the M13 forward and M13 reverse 
primer, indicating there is no contamination with bacmid that did not undergo Tn7 
transposition. 
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protein GP64, the SeF protein instead of GP64, or had both GP64 and SeF.  The 
recombinant viruses were confirmed by PCR analysis using primers specific to the GUS 
gene and the envelope protein genes (Fig. 2.4).  A list of the recombinant viruses 
generated for this study is shown in Table 2.4.  The recombinant viruses were also 
confirmed by Western blot analysis using antibodies against the envelope proteins GP64.  
As expected, Western blots of lysates of vAcCMV-hrGFP, vgp64nullAcGP64-CMV-hrGFP, and 
vAcSeF-CMV-hrGFP infected cells probed with anti-GP64 had the predicted 64 kDa band, but 
the band was absent in lanes containing lysates from vgp64nullAcSeF-CMV-hrGFP infected 
cells (Fig. 2.5).  Since AcMNPV will not propagate without GP64 or a functional 
substitute such as SeF (Lung et al., 2002), the absence of GP64 in vgp64nullAcSeF-CMV-
hrGFP infected cell lysates strongly suggest that SeF protein is expressed. 
 
2.3.2 GP64-containing AcMNPV can transduce a variety of non-insect cell lines. 
The transduction efficiencies of the four recombinant AcMNPV variants were compared 
by counting the percentage of GFP positive cells 24 hour after transduction.  Although the 
transduction efficiency is cell line dependent, results for a particular cell line show that 
the two GP64-containing and SeF negative viruses had comparable transduction 
efficiencies (Table 2.5, Fig. 2.6).  GP64-containing virus transduced human HepG2 cells 
very efficiently, with greater than 96% of the cells positive for GFP expression (Fig. 2.7).  
The transduction efficiency of vAcCMV-hrGFP was approximately 73.24% for monkey 
VERO cells, 63.74% for feline FKC cells, 55.33% for porcine PK-15 cells, 33.85% for 
porcine ST cells, 6.6% for canine MDCK cells, and 5.31% for chicken UMNSAH/DF-1 
cells.  Of the four fish-derived cell lines tested, the transduction efficiency was 2.2% for 
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RTG-2 cells, 13.29% for SSN-1 cells, 14.99% for CHES-214 cells, and 50.74% for EPC 
cells.   
 
2.3.3 SeF pseudotyped gp64null-AcMNPV do not transduce any of the non-insect cell 
lines efficiently. 
Transduction of SeF-pseudotyped gp64null-AcMNPV (vgp64nullAcSeF-CMV-hrGFP) was 
done in parallel with the three gp64-containing viruses to examine whether SeF 
pseudotyping could be used to narrow the tropism of AcMNPV for vertebrate cells.  
Results show the transduction efficiencies of the SeF-pseudotyped gp64null virus on all 
tested cell lines were lower than the control viruses (vgp64nullAcGP64-CMV-hrGFP).  At a moi 
of 500, the transduction efficiencies of vgp64nullAcSeF-CMV-hrGFP were highest on fish 
EPC, SSN-1 and CHES-214 cells, with efficiencies of approximately 1.31%, 5.22%, and 
2.95%, respectively.  The value for EPC is significantly lower than the 43.28% seen with 
the vgp64nullAcGP64-CMV-hrGFPcontrol virus.  Expression of GFP was observed in less than 
0.2% of the porcine ST, murine McCOY, feline FKC, monkey Vero, hamster BHK-21, 
and human HepG2 cells transduced with the vgp64nullAcSeF-CMV-hrGFP virus.  These values 
represent a significant drop from the approximately 95% for HepG2 cells, 85% for BHK-
21 cells, 69.32% for VERO cells, and 59.08% for FKC cells.  No GFP positive cells were 
observed in canine MDCK, porcine PK-15, fish RTG-1, and chicken UNMSAH-DF-1 
cells transduced with vgp64nullAcSeF-CMV-hrGFP whereas the transduction efficiency of PK-
15 by the vgp64nullAcGP64-CMV-hrGFP control virus was 50.28% (Table. 2.5, Fig. 2.6).  The 
low or lack of transduction by the vgp64nullAcSeF-CMV-hrGFP virus is not due to lack of 
functionality of the CMV-hrGFP cassette in these cells as cells transduced with the GP64-
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containing variants showed GFP expression.  To rule out the possibility that the lack of 
transduction is due to virus inactivation, post-transduction inoculums were added to 
insect Sf9 cells to assay for the presence of infectious virus.  Results show that all post-
transduction inoculums contain infectious viruses that are capable of infecting Sf9 cells, 
indicating the low transduction efficiencies observed with vgp64nullAcSeF-CMV-hrGFP were 
not due to virus inactivation (Fig 2.8).   
 
Since several of the mammalian cell lines can be transduced inefficiently by the 
vgp64nullAcSeF-CMV-hrGFP virus at a moi of 500, transduction was also performed at a moi 
of 50 on HepG2, BHK-21, VERO, ST, FKC and McCOY cells to determine if a lower 
moi could eliminate transduction.  Results show that no GFP positive cell was observed 
in six cell lines tested when transduced with vgp64nullAcSeF-CMV-hrGFPat a moi of 50 (data 
not shown).  These results indicate that the tropism of vgp64nullAcSeF-CMV-hrGFP for 
mammalian cells can be lowered further by using a lower virus to cell ratio.   
 
2.3.4 Observation of Cell-cell fusion in bovine MDBK and ovine SCP cells 
transduced with GP64-containing AcMNPV. 
An interesting observation made during this study was that bovine MDBK and sheep SCP 
cells transduced with GP64-containing viruses fused into large syncytiums by 24 hour 
post transduction (hpt).  Cell fusion was not observed in experiments where cells were 
transduced with vgp64nullAcSeF-CMV-hrGFP, which does not have GP64, indicating the 
fusion of MDBK and SCP cells is due to the presence of GP64.  When the kinetics of 
syncytium formation was examined by observing cells at various time points after a two 
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hour transduction by vAcCMV-hrGFP, cell-cell fusion of MDBK cells was first observed at 
3hpt (Fig. 2.9).  These results suggest that under certain circumstances, GP64 may have 
membrane fusion activity in the absence of low pH activation. 
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Fig. 2.4 Confirmation of recombinant AcMNPV variants by PCR analysis. Viral DNA 
were extracted from Sf9 cells that were either mock infected (lanes 1, 6, 11), or infected 
with vAcCMV-hrGFP (lanes 2, 7, 12), vgp64nullAcGP64-CMV-hrGFP (lanes 3, 8, 13), vAcSeF-CMV-
hrGFP (lanes 4, 9, 14), vgp64nullAcSeF-CMV-hrGFP virus (lanes 5, 10, 15), and amplified by 
PCR using primer pairs specific to the GUS gene (lanes 1-5), the gp64 gene (lanes 6-10), 
or the SeF gene (lanes 11-15). 
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Fig. 2.5 Western-blot analysis of cell lysates from mock infected Sf9 cells (lane 1), Sf9 
cells infected with vAcCMV-hrGFP (lane 2), vgp64nullAcGP64-CMV-hrGFP (lane 3), vAcSeF-CMV-
hrGFP (lane 4), and vgp64nullAcSeF-CMV-hrGFP (lane 5). Cells were infected at a moi of one 
and cell lysates were harvested at 72 hpi. The Western blot was probed with an anti-GP64 
monoclonal antibody (AcV5). 
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Table 2.4 Virus generated in this study. 
 
Virus 
mammalian 
reporter gene 
envelope protein genes (locus) Bacmid backbone 
vgp64nullAcCMV-hrGFP hrGFP none gp64null-bMON14272 
vAcCMV-hrGFP hrGFP gp64 (gp64 locus) DH10-bMON14272 
vgp64nullAcGP64-CMV-hrGFP hrGFP gp64 (polyhedrin locus) gp64null-bMON14272 
 
vAcSeF-CMV-hrGFP 
hrGFP gp64 (gp64 locus) + SeF (polyhedrin locus) DH10-bMON14272 
vgp64nullAcSeF-CMV-hrGFP hrGFP SeF (polyhedrin locus) gp64null-bMON14272 
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Table 2.5 Transduction efficiencies of four recombinant AcMNPV variants on 14 
different cell lines (500 moi). 
Source/Cell Tissue of origin Virus 
Cell 
count 
Transduction 
efficiency (%) SD 
Human  vAcCMV-hrGFP ~358 96.9% ND* 
HepG2 
 vgp64nullAcGP64-CMV-hrGFP ~718 98.47% ND* 
Liver vAcSeF-CMV-hrGFP ~622 99.68% ND* 
  vgp64nullAcSeF-CMV-hrGFP ~1642 0.15% ND* 
Monkey  vAcCMV-hrGFP 1468 73.24% 9.08% 
VERO 
 vgp64nullAcGP64-CMV-hrGFP 1558 69.32% 12.48% 
Kidney vAcSeF-CMV-hrGFP 1852 84.02% 6.07% 
  vgp64nullAcSeF-CMV-hrGFP 2202 0.18% 0.31% 
Mouse  vAcCMV-hrGFP 2440 2.91% 1.2% 
McCOY 
 vgp64nullAcGP64-CMV-hrGFP 1945 5.91% 4.86% 
Fibroblasts vAcSeF-CMV-hrGFP 2487 7.64% 1.6% 
  vgp64nullAcSeF-CMV-hrGFP 2290 0.13% 0.28% 
Porcine  vAcCMV-hrGFP 600 55.33% 14.64% 
PK-15 
 vgp64nullAcGP64-CMV-hrGFP 535 50.28% 13.96% 
Kidney vAcSeF-CMV-hrGFP 609 55.01% 8.27% 
  vgp64nullAcSeF-CMV-hrGFP 539 0.00% 0.00% 
  vAcCMV-hrGFP 1681 33.85% 7.01% 
ST 
 vgp64nullAcGP64-CMV-hrGFP 1658 41.25% 8.21% 
Testicle vAcSeF-CMV-hrGFP 1124 39.5% 6.78% 
  vgp64nullAcSeF-CMV-hrGFP 1469 0.14% 0.31% 
Feline  vAcCMV-hrGFP 1536 63.74% 5.60% 
FKC 
 vgp64nullAcGP64-CMV-hrGFP 1200 59.08% 8.12% 
Kidney vAcSeF-CMV-hrGFP 1162 64.20% 5.68% 
  vgp64nullAcSeF-CMV-hrGFP 1180 0.17% 0.42% 
Canine  vAcCMV-hrGFP 788 6.60% 6.56% 
MDCK 
Kidney 
epithelial  vgp64nullAc
GP64-CMV-hrGFP 986 6.39% 4.51% 
Kidney vAcSeF-CMV-hrGFP 935 5.35% 4.49% 
  vgp64nullAcSeF-CMV-hrGFP 884 0.00% 0.00% 
 
Chicken  vAc
CMV-hrGFP 1093 5.31% 3.38% 
UMNSAH/DF-1 
Embryo 
Fibroblast 
vgp64nullAcGP64-CMV-hrGFP 898 10.13% 2.39% 
vAcSeF-CMV-hrGFP 1066 7.41% 4.62% 
  vgp64nullAcSeF-CMV-hrGFP 451 0.00% 0.00% 
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Bovine  vAcCMV-hrGFP 
Cell fused   vgp64nullAcGP64-CMV-hrGFP 
MDBK Kidney vAc
SeF-CMV-hrGFP 
  vgp64nullAc
SeF-CMV-hrGFP 1456 0.34% 0.57% 
Ovine  vAcCMV-hrGFP 
Cell fused   vgp64nullAcGP64-CMV-hrGFP 
SCP Choroid 
plexus 
vAcSeF-CMV-hrGFP 
 vgp64nullAc
SeF-CMV-hrGFP ~2042 0% 0% 
Fish  vAcCMV-hrGFP 1089 2.20% 1.76% 
RTG-2 
 
Gonad 
vgp64nullAcGP64-CMV-hrGFP 1155 3.03% 3.91% 
vAcSeF-CMV-hrGFP 1176 1.87% 1.05% 
  vgp64nullAcSeF-CMV-hrGFP 950 0.00% 0.00% 
   vAcCMV-hrGFP 
 
1293 
 
13.29% 
 
3.85% 
SSN-1 
 
Whole fry 
tissue vgp64nullAc
GP64-CMV-hrGFP 1744 7.65% 2.6% 
 
  vAc
SeF-CMV-hrGFP 1294 17.21% 8.04% 
  vgp64nullAcSeF-CMV-hrGFP 1519 5.22% 1.68% 
  vAcCMV-hrGFP 1488 14.99% 15.34% 
CHES-214 
 
 
Salmon 
embryos vgp64nullAc
GP64-CMV-hrGFP 1432 19.41% 3.55% 
 
  
vAcSeF-CMV-hrGFP 1289 26.76% 6.16% 
vgp64nullAcSeF-CMV-hrGFP 1864 2.95% 1.63% 
 
Epithelioma 
  
vAcCMV-hrGFP 339 50.74% 10.58% 
EPC vgp64nullAcGP64-CMV-hrGFP 67 43.28% 15.89% 
 
vAcSeF-CMV-hrGFP 129 46.51% 8.46% 
vgp64nullAcSeF-CMV-hrGFP 689 1.31% 1.54% 
*ND: not determinated. 
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Fig 2.6 Transduction efficiencies of 11 vertebrate cell lines by four recombinant AcMNPV variants.  Cells were scored for GFP 
expression at 24 hpt transduction with  vAcCMV-hrGFP  (red),  vgp64nullAcGP64-CMV-hrGFP (orange), vAcSeF-CMV-hrGFP (green), and 
vgp64nullAcSeF-CMV-hrGFP.  Transduction efficiencies were not shown for HepG2, MDBK, and SCP due to the cell clumping of HepG2 
cells and cell-cell fushion for MDBK cells and SCP cells.
vAcCMV-hrGFP
vgp64nullAcGP64-CMV-hrGFP 
vAcSeF-CMV-hrGFP 
vgp64nullAcSeF-CMV-hrGFP 
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Fig. 2.7 Representative fluorescent micrographs of human HepG2 cells transduced with 
the four AcMNPV variants. DAPI fluorescence of stained cell nuclei is shown in the left 
column, and GFP fluorescence in shown in the right column. The viral variant used for 
the transduction is shown on the left of the images. 
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Fig. 2.8 Representative example of GUS activity assay performed to confirm the 
presence of infectious virions in the post-transduction inoculums. Post-transduction 
inoculums from PK-15 and MDCK cells that were mock transduced (M), or transduced 
with vAcCMV-hrGFP (G(g)), vgp64nullAcGP64-CMV-hrGFP (G(p)), vAcSeF-CMV-hrGFP, (G(g)+S), 
vgp64nullAcSeF-CMV-hrGFP (S) were added to Sf9 cells.  Substrate for GUS was added to the 
Sf9 cells at 3 day post infection to detect GUS expression in virus infected cells. 
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Fig. 2.9 Syncytium formation in MDBK cells after transduction with vAcCMV-hrGFP. A) 
mock transduced, B) 3 C) 7 hour post transduction (hpt) with vAcCMV-hrGFP. Cell-cell 
fusion can be clearly observed at 3 hpt (arrow). 
 
 51
2.4 Discussion 
 
Several lines of evidence suggest that GP64, the envelope protein of AcMNPV BV play a 
critical role in the transduction of non-insect cells by AcMNPV (Tani et al., 2001; Liang 
et al., 2005).  However, similar evidence suggests that F proteins from group II NPV can 
not mediate viral entry into mammalian cells (Liang et al., 2005; Westenberg et al., 
2007).  To examine the impact GP64 and F have on transduction of vetebrate cells, 
recombinant AcMNPV viruses with either a single copy of the gp64 gene, a single copy 
of the SeF gene, or with a single copy of both genes were generated.  The transduction 
efficiency of four recombinant AcMNPV variants with a different repertoire of envelope 
proteins were tested on 15 cell lines derived from human, monkey, porcine, feline, 
canine, bovine, ovine, avian, and fish species.  Transduction of SeF-pseudotyped 
gp64null-AcMNPV is reported for the first time for 12 cell lines and the transduction 
efficiency for AcMNPV with the endogenous GP64 protein is reported for the first time 
for feline FKC (59.8%), porcine ST (33.85%), chicken UMNSAH/DF-1 (5.31%), and 
fish SSN-1 (13.29%) cells in this study.  Furthermore, transduction of vertebrate cells by 
AcMNPV carrying both GP64 and SeF envelope proteins are also reported for the first 
time.  Results show that GP64-containing AcMNPV can efficienctly transduce liver 
(HepG2) and many kidney-derived cell lines (BHK-21, VERO, PK-15, FKC) except for 
the two kidney epithelial cell lines (canine MDCK and bovine MDBK).  These results are 
consistent with a previous report that transduction efficiency of hepatocyte-derived cell 
lines (Huh7, HepG2) and primary hepatocytes (phH, pw-rH) using recombinant 
AcMNPV carrying a CMV-luciferase reporter gene were significantly higher than other 
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cell lines tested, whereas transduction of MDCK cells is very poor (Hofmann et al., 
1995).  A previous report has also shown that kidney-derived cell lines (BHK, 293, COS-
7, PK-15) and primary mouse kidney cells (MKC) could be efficiently transduced with 
Ac-CMV-GFP (Liang et al., 2004).  The results presented here also showed that all three 
of the gp64-containing viruses can transduce fish EPC (43%~51%) and CHES-214 
(17%~27%) cells with moderate efficiency and RTG-2 cells with low efficiency 
(1.87%~3.3%).  This is somewhat unexpected since it has been reported that transduction 
efficiency of fish EPC (0.04-2%) and CHES-214 (0.05%) cells was extremely low, and 
undetectable for RTG-2 cells when transduced with a fairly similar virus to ones used in 
this study (Ac-CAlacZ), but carrying a different reporter gene cassette (Leisy et al., 
2003).  This inconsistency is most likely due to the different promoter used to drive 
reporter gene expression.  A CMV promoter was used in this study, while the CAG 
promoter was used by Leisy et al. (2003).  The higher moi (500 vs. 200), and the longer 
duration of transduction (6 hour vs. 1 hour) used in this study may also have contributed 
to the higher transduction efficiency observed in this study.  Thus my results indicate fish 
cell lines are susceptible to AcMNPV transduction.   
 
SeF-pseudotyped gp64null-AcMNPV transduction of cell lines derived from chicken, fish 
and mammalian species were done in parallel with three gp64-containing control viruses.  
All cell lines tested showed little or no transduction by the vgp64nullAcSeF-CMV-hrGFP virus.  
This virus did not appear to transduce chicken UMNSAH/DF-1, canine MDCK, porcine 
PK-15, and fish RTG-2 cells.  Some transduction of porcine ST, mouse McCOY, feline 
FKC, monkey Vero, hamster BHK-21, and human HepG2 cells was detected but the 
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efficiency was low (< 0.2%).  However, transduction of ST and McCOY cells were not 
detected when transduction was carried out using a lower moi of 50, indicating the 
transduction of these cell types can be further diminished by using a lower virus to cell 
ratio.  The three fish cell lines (EPC, SSN-1 and CHES-214) had the highest transduction 
efficiency of the cell lines tested (1.31-5.22%).  The inefficient or lack of transduction by 
the SeF-pseudotyped gp64null-AcMNPV is not due to inactivation of the viruses, nor was 
it due to lack of CMV-hrGFP reporter cassette activity in these cell lines.  These results 
indicate that SeF-pseudotyped gp64null-AcMNPV have significantly narrower tropism 
for vetebrate cells than AcMNPV with the endogenous envelope protein GP64.  The 
presence of SeF in addition to GP64 on the virion did not significantly increase the 
transduction efficiency of most cell lines.  However, transduction efficiencies of VERO, 
McCOY, ST, FKC, SSN-1 and CHES-214 cells were slightly increased when both 
envelope proteins are present (vAcSeF-CMV-hrGFP).  Interestingly, these were the cell lines 
that showed detectable transduction by the viruse with SeF in place of GP64, suggesting 
that the presence of SeF can enhance the transduction of certain cell lines that are 
transduced by the SeF-pseudotyped gp64null-AcMNPV virus.  Consistent with this 
hypothesis, the presence of SeF did not effect the transduction efficiency of most other 
cell lines (PK-15, MDCK, UMNSAH/DF-1, RTG-2) that were not transduced by SeF-
pseudotyped gp64null-AcMNPV. 
 
Recently Westenberg et al. (2007) reported that SeF-pseudotyped gp64null-AcMNPV 
carrying a CMV-eGFP reporter cassette showed no detectable GFP fluorescence in 
mammalian BHK-21, LLC-PK1, and H35 cells when the transduction was performed at 
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37°C for 2 hours using a moi of 100.  In this study, positive but extremely low 
transduction efficiency was found in mammalian BHK-21, as well as ST, McCOY, FKC, 
Vero, and HepG2 cells.  This inconsistency might be due to the following reasons: 1) the 
higher transduction moi used in this study (500 moi vs. 100 moi); 2) a longer transduction 
duration used in this study (6 hour vs. 2 hour); and 3) differences in the temperature and 
the media in which transduction was carried out.  The transduction media and 
temperature used in this study (25°C in Dulbecco’s phosphate-buffered saline , D-PBS) 
has been reported to give higher transduction efficiency when compared with the 
tranditional transduction protocol (37°C in cell culture medium) used by Westenberg et 
al. (Hsu et al., 2004). 
 
GP64 has been well characterized to be a low-pH dependent membrane fusion protein in 
insect cells (Blissard and Wenz, 1992).  Membrane fusion by GP64 in the absence of low 
pH activation has not been reported.  My observation that MDBK and SCP cells can be 
induced to fuse under neutral pH after AcMNPV transduction, suggest that GP64 may 
mediate cell fusion without low-pH activation under certain circumstances.  The 
mechanism by which GP64 mediates fusion of these cells remains to be determined.    
 
Kitagawa et al. (2005) showed that gp64null-AcMNPV pseudotyped with CD46 or 
SLAM (receptors of measles virus) can specifically transduce BHK cells expressing 
measles virus envelope glycoproteins, indicating that pseudotyped gp64-null AcMNPV 
displaying targeting molecules can be used for targeted gene delivery.  However, these 
pseudotyped gp64-null AcMNPVs lack the essential gp64 gene, can not be amplified, and 
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therefore have very limited practical use.  Since SeF-pseudotyped gp64null-AcMNPV can 
be amplified to high titer, and appears to significantly narrow the tropism for mammalian 
cell lines, this virus may be useful as a platform for further addition of targeting 
molecules for targeted gene delivery.  Additional advantages of the SeF-pseudotyped 
gp64null-AcMNPV platform for target cell-specific gene delivery include the fact that 
targeting molecules (e.g., ligands or envelope protein of heterologous virus) can be easily 
engineered into the SeF-pseudotyped gp64null-AcMNPV genome for ligand-directed cell 
targeting.  Strategies such as the engineering of viral surface proteins can be further 
combined with the use of tissue-specific promoters for tissue specific gene expression to 
further decrease detrimental effects that may be caused by misexpression of transgenes in 
unintended target cells.  
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Chapter 3.  Autographa californica Multicapsid Nucleopolyhedrovirus (AcMNPV) 
ORF 23 null mutant produces occlusion-derived virions with fewer nucleocapsids. 
 
3.1 Introduction. 
 
Baculovirus constitute a large and diverse family of enveloped viruses with rod shaped 
nucleocapsids, and a circular double stranded DNA genome that ranges in size from 80 
kbp to 180 kbp (Blissard et al., 2000).  Baculovirus are restricted to arthropod hosts and 
have been isolated from more than 600 host species.  The type baculovirus, Autographa 
californica multicapsid nucleopolyhedrovirus (AcMNPV), has a biphasic life cycle in 
which two virion phenotypes with distinctively different roles are produced in the same 
cell (Miller et al., 1997).  Budded viruses (BVs) are produced early in infection when 
nucleocapsids acquire an envelope by budding through the plasma membrane of the 
infected cell.  BVs infect a variety of cell types and are responsible for the systemic 
spread of viral infection within a host (Granados et al., 1981; Engelhard et al., 1994; 
Federici et al., 1997; Mangor et al., 2001).  In contrast, occlusion-derived virions (ODVs) 
are produced late in infection when nucleocapsids become enveloped within the nucleus 
(for review, see reference Slack and Arif, 2006).  ODVs are subsequently encapsulated 
within the nucleus by polyhedrin proteins to form proteinaceous, polyhedral crystal-like 
structures called occlusion bodies (OBs).  OBs are released upon host cell lysis and are 
believed to protect ODVs from detrimental factors present in the dying host and the 
environment.  Upon ingestion of OBs by susceptible hosts, the alkaline environment of 
the host’s midgut triggers OB disassembly and ODV release.  ODVs are highly infectious 
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to midgut epithelial cells and establish the primary infection in the animal midgut after 
which BVs spread the infection systemically (Granados et al., 1981; Keddie et al., 1985, 
1989; Mangor et al., 2001; Monsma et al., 1996). 
 
Baculovirus are currently classified into two genera; the Nucleopolyhedroviruses (NPVs) 
(Rohrmann, 1999) and the Granuloviruses (GVs) (Wormleaton et al., 2003).  NPVs from 
Lepidopteran hosts have been further classified into group I and group II based on 
molecular phylogenetic analysis (Bulach et al., 1999; Herniou et al., 2001, 2003; Zanotto 
et al., 1993).  The NPVs are also further divided into single capsid 
nucleopolyhedroviruses (SNPVs) and multicapsid nucleopolyhedroviruses (MNPVs).  
SNPV ODVs contain a single nucleocapsid, while MNPV ODVs contain multiple 
nucleocapsids.  The biological basis for SNPV and MNPV has not been determined, and 
it has been suggested that the single and multiple capsid morphotypes have no 
phylogenetic relevance (Herniou et al., 2003).  However, biological assays done on 
related, but not identical MNPV and SNPV virus, support the hypothesis that the MNPV 
has advantages over the SNPV in per os infectivity (Washburn et al., 1999, 2003). 
 
Envelope fusion proteins are important structural proteins that mediate entry of 
enveloped viruses into host cells.  BVs enter by receptor-mediated endocytosis and their 
envelope proteins mediate fusion of the viral envelope with endosome membranes after 
endosomal acidification (Blissard and Wenz, 1992; Volkman and Goldsmith., 1985).  Two 
different BV envelope fusion proteins have been identified in the family baculoviridae: 
GP64 and F protein (for review, see reference Pearson and Rohrmann, 2002).  GP64 has 
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been well characterized to be a low pH-activated membrane fusion protein that is 
essential for BV attachment, fusion and budding (Hefferon et al., 1999; Oomens et al., 
1999).  Early baculovirus literature based mostly on the group I baculovirus AcMNPV 
and OpMNPV pointed to GP64 as the primary baculovirus BV envelope fusion protein.  
However it was later discovered that the genomes of group II NPVs such LdMNPV and 
SeMNPV (IJkel et al., 1999; Kuzio et al., 1999) lacked gp64 homologues.  This led to the 
identification of f (short for fusion) genes.  The f genes show no sequence similarity to 
gp64, but LdMNPV F protein (Ld F or Ld130) and SeMNPV F protein (SeF or Se8) both 
had low pH-activated membrane fusion activity (IJkel et al., 2000; Pearson et al., 2000), 
and could rescue a gp64-null AcMNPV mutant virus (Lung et al., 2002).  All sequenced 
group II NPVs, GVs and Dipteran baculovirus lack gp64 homologues and have f gene 
homologs (Hiscock et al., 2000).  The only sequenced baculovirus genomes which lack 
both f genes and gp64 genes are three Hymenopteran (sawfly) baculovirus (NeabNPV, 
NeseNPV and NeleNPV) (Duffy et al., 2007; Garcia-Maruniak et al., 2004; Keddie et al., 
1985).  These viruses may however lack the BV phenotype. 
 
Despite their having gp64 gene homologues, f gene homologs are also found in group I 
NPV baculovirus genomes.  Even more intriguing was the discovery that the F homologs 
of group I NPVs, AcMNPV (Ac23) and OpMNPV (Op21) do not have detectable 
membrane fusion activity (Lung et al., 2003; Pearson et al., 2000).  Since the f genes are 
more divergent and more widely distributed within the baculoviridae than gp64, it has 
been proposed that gp64 was a more recent acquisition by ancestors of group I NPVs 
(Pearson et al., 2000) and that gp64 subsequently supplanted the membrane fusion 
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function of the F protein.  Homologs of the f gene have been identified in several 
Dipteran and Lepidopteran insect species suggesting that f genes may have been acquired 
from an insect host (Lung et al., 2005).  Characterization of an Ac23-null mutant 
AcMNPV virus showed that this gene is not essential for viral replication and infectivity 
in cultured cells or in animals (Lung et al., 2003).  However, animals infected with Ac23-
null mutant viruses survived longer (Lung et al., 2003).  In the present study we used 
confocal microscopy to show that Ac23-GFP localizes to the nuclear envelope, and 
electron microscopy (EM) to show that absence of Ac23 correlated with an alteration in 
ODV composition (nucleocapsid number).  How this in turn, affects pathogenesis in host 
animals will be discussed.  
 
3.2 Materials and Methods 
 
3.2.1. Cell culture and virus production. 
Spodoptera frugiperda (Sf9) cells were cultured at 27°C in TNMFH supplemented with 
10% (v/v) fetal bovine serum (Hyclone, Logan, UT).  The AcMNPV strain E2 virus was 
used as a wildtype (wt) control in the analysis along with three genetically modified 
bacmid-derived viruses.  All viruses were amplified using Sf9 cells, and viral titers were 
determined by endpoint dilution.  All three of the bacmid-derived viruses are derived 
from the bacmid bMON14272 (Invitrogen, Carlsbad, CA) and have been described 
previously (Lung et al., 2003).  The genome of the bacmid-derived control virus 
vAcbacmid/GUS+PH (Acbacmid) was generated by Tn7-mediated transposition of the vector 
p∆FBgus(R)-polyhedrin which contained a polyhedrin gene under the control of a 
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polyhedrin promoter and a GUS reporter gene under the control of a P6.9 promoter into 
the bacmid bMON14272.  The vAc23null/GUS+PH (Ac23null) mutant virus genome was 
generated by replacing the Ac23 gene in bMON14272 with a CAT gene, and an insertion 
of the polyhedrin gene from p∆FBgus(R)-polyhedrin into the polyhedrin locus by Tn7-
mediated transposition.  The vAc23null/GUS+Ac23+PH (Ac23null-repair) virus is the control 
of the Ac23null mutant virus as it contains the same CAT replacement of Ac23 gene as 
that of the Ac23null virus.  The Ac23 gene, however, was reintroduced into the 
polyhedrin locus of the Ac23 knockout bacmid along with a GUS reporter gene and a 
polyhedrin gene using Tn7-mediated transposition.  Genotypes of the viruses were 
confirmed by PCR analysis.  Two viruses carrying the Ac23-GFP transgene were 
generated for examination of Ac23 localization by confocal microscopy.  The Ac23GFP 
fusion gene was PCR amplified from pH5Ac23 (a gift from Dr. Rollie Clem, Kansas State 
University) and cloned into PCR-II blunt vector (Invitrogen) to generate pAc23GFP-
PCRII-blunt.  The PCR derived region was confirmed by sequencing.  The Ac23GFP 
gene was subsequently cloned into the vector p∆FB-gus(R)-polyhedrin using BamHI and 
HpaI sites to generate the shuttle vector p∆FB-gus(R)-Ac23GFP-polyhedrin.  The Ac23-
GFP gene under the control of the Ac23 promotor was then introduced into an Ac23null 
bacmid, and an Ac23-containing bacmid by Tn-7 mediated transposition.  The 
recombinant bacmids were used to generate two Ac23-GFP fusion gene carrying viruses 
vAc23null/GUS Ac23GFP+PH (Ac23null-Ac23GFP repair) and vAcBAC+/ GUS Ac23GFP+PH 
(Acbacmid-Ac23GFP).   
 
OBs were produced by infecting Sf9 cells (9 x 106 cells/T150 flask) with budded virus at a 
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multiplicity of infection of five. At seven days post infection, OB were purified from 
infected cells as described by O’Reilly et al. (1994), re-suspended in sterile water, and 
stored at 4°C.  Prior to use, the OB suspension was gently vortexed for 20 min at room 
temperature to break up any aggregates that may have formed. 
 
3.2.2 Scanning Electron Microscopy (SEM) 
OBs were first captured by passing OB suspensions through a 0.4 µm polycarbonate filter 
(Nuclepore, Kent, WA), fixed for 1 hr at room temperature with 500 µL of modified 
Karnovsky’s buffer (2.5% glutaraldehyde, 4% paraformaldehyde, 0.1 M sodium 
cacodylate buffer, pH 7.2) and then washed with 0.1 M sodium cacodylate buffer, pH 7.2 
for 10 min at room temperature.  OBs were then dehydrated at room temperature using 
500 µL of each of the following graded ethanol series for 5 min each: 50%, 70%, 85%, 
90%, and 100%.  The ethanol was then removed and replaced with 500 µL of a 50:50 
mixture of hexamethyldisilazane (HMDS) and absolute ethanol for 10 min, and then 
twice for 10 min each with 100% HMDS.  The filters were then air-dried inside a fume 
hood for 1 hr and placed on aluminum mounts (Ted Pella, Inc., Redding, CA) using 
carbon tags (Marivac Limited, Halifax, NS).  The samples were sputtered coated using a 
Polaron E5100 series II Sputter Coater (BioRad, Hercules, CA) and then photographed at 
6000 x magnification using a Hitachi S-500 scanning electron microscope.  Two 
perpendicular measurements (L1 and L2) across the widest region of each OB structure 
were taken as a measure of OB sizes. 
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3.2.3. Transmission Electron Microscopy (TEM) 
Sample preparation for TEM was performed as described by Hong et al. (1994).  OBs 
were pelleted at 14,100 x g for 8 min in a mini-spin microfuge (Eppendorf, Bristol, CT) 
and fixed for 1 hr in modified Karnovsky’s buffer.  Fixed OB were pelleted and 
encapsulated in 20 µl of 4% (w/v) low melting point agarose.  The agarose block was 
washed with 0.1 M sodium cacodylate, pH 7.2 for 30 min at 4oC and then incubated in a 
post-fixing solution (1% osmium tetroxide, 0.1 M sodium cacodylate, pH 7.2) for 1 hr at 
room temperature.  The fixed samples were washed again and dehydrated at room 
temperature with the following graded ethanol series: 50%, 70%, 85%, 90% for 15 min 
each, 95% for 1 hr, and twice with 100% ethanol for 30 min each.  Samples were then 
infiltrated with 25%, 50%, and 75% Spurr’s resin/ethanol series (v/v, 12 hours each step).  
Final infiltration was performed in 100% Spurr’s epoxy resin at room temperature for 30 
min, followed by an overnight incubation (~16 hr).  The resin was then polymerized in a 
60°C oven for approximately 24 hr.  Sections were cut with a Reichert Om U3 
ultramicrotome at various thicknesses and mounted on either copper slot (1 x 2 mm) grids 
containing formvar and carbon film (serial sections), or 200 mesh copper grids (non-
serial sections).  All sections were stained in 5% uranyl acetate (10 min) followed by 
Reynolds lead citrate (1 min) before examining and photographing using an Hitachi H-
600 TEM operated at 75kV. 
 
A. Serial sections of viruses’ occlusion bodies. 
Serial sections of 100 nm thickness (AcMNPV E2 and Acbacmid) and 200 nm thickness 
(Ac23null mutant virus) were cut and photographed at 6000 x magnification (AcMNPV 
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E2 and Acbacmid) and 5000 x magnification (Ac23null mutant).  Independent OBs were 
identified, numbered and followed through consecutive sections.  The longest diameter 
(L1) in the section containing the widest OB was measured from the micrograph.  The 
longest perpendicular measurement relative to L1 was taken (L2) and the average of L1 
and L2 was used as a measure of the size of the OB.  The number of ODV particles in 
each widest OB section was also determined. 
 
B. Non-serial sections of Ac23null mutant and control virus occlusion bodies. 
Individual 100 nm thick sections of the four viruses were examined by TEM and 
photographed at 10,000 x magnification for determination of the number of 
nucleocapsids in each ODV.  To ensure ODVs observed in the individual sections were 
truly independent, every fifth section was kept for analysis and intervening sections were 
discarded.  Only transverse sections of ODVs that were well stained and had a clear 
envelope were chosen for nucleocapsid calculation.  ODVs that clearly had more than 
five nucleocapsids, but for which the exact number could not be accurately determined, 
were grouped into a separate class.  
 
3.2.4. Confocal Microscopy 
To examine Ac23 localization by confocal microscopy, Sf9 cells were seeded into glass 
bottom culture dishes (9 x 105 cells per dish) (MetTek, Ashland, MA) and incubated for 1 
hr at 27°C.  Cells were then either mock infected, infected with a GFP-minus control 
virus (Ac23null-repair), or infected with viruses carrying Ac23-GFP transgenes 
(Ac23null-Ac23GFP repair and Acbacmid-Ac23GFP).  At 48 and 77 hours post infection, 
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medium was removed and cells were fixed with 10% formalin for two min, washed with 
PBS once, stained with 300 nM DAPI (Invitrogen, Carlsbad, CA) in PBS for three min, 
and rewashed three times with PBS.  Cells were observed with a Nikon C1+ confocal 
microscope using a 405 diode laser for DAPI and an Argon 488 laser for GFP.  
Differential interference contrast (DIC) imaging was used to provide contrast to the 
unstained cells.  All images were captured using X60/1.2 N.A. water immersion lens. 
   
3.2.5. Statistical Methods 
Data analysis was done using SPSS 15.0 software (SPSS Inc. Chicago, IL).  Statistical 
analysis consisted of determinations of mean and standard deviation of viral particle size.  
Pearson correlation coefficient was used to test the trend for an association between the 
number of ODV particles and the size of the widest OB section.  A simple linear 
regression model was applied to evaluate the prediction of ODV numbers from the size of 
the widest OB section. Group differences were compared by ANOVA test and Tukey test.  
All p values were determined by two-tailed test and p values less than 0.05 was regarded 
as statistically significant.  
 
3.3 Results 
 
3.3.1. OBs from bacmid-derived viruses are smaller than those of wildtype viruses 
During previous OB quantitation by light microscopy, it was observed that OBs from 
Ac23null viruses appeared smaller than OBs from control AcMNPV (unpublished 
observation).  In the present study we made detailed measurements of OB size using both 
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SEM and TEM.  A schematic diagram of the genetic differences between the Ac23null 
virus and three control viruses used in the present study is presented in Figure 3.1.  Since 
OBs are polyhedral crystals, I used the average of the two largest perpendicular length 
measurements as a measure of OB size.  SEM analysis showed that OBs from all four 
groups of viruses showed intra-group size variation (Fig. 3.2).  Significant size 
differences were found between wildtype (AcMNPV E2) OBs and OBs from the bacmid-
derived viruses using the ANOVA test and Tukey test (Fig. 3.3, p<0.0001).  Wildtype 
OBs are generally larger than OBs of the Ac23null-repair virus (mean ± SD, 2.48 ± 0.60 
vs. 1.62 ± 0.44 µm, p<0.0001), the bacmid-derived control Acbacmid (2.48 ± 0.60 vs. 
1.74 ± 0.44 µm, p<0.0001) and the Ac23null mutant (2.48 ± 0.60 vs. 1.75 ± 0.54 µm, 
p<0.0001).  However, there was no significant difference between the sizes of OB from 
the two bacmid-derived control viruses (Ac23null-repair and Acbacmid), and between the 
bacmid-derived control viruses and the Ac23null virus using the ANOVA test and Tukey 
test.  The sizes of OBs were also determined by measuring the widest OB cross section 
found in TEM serial sections of purified agarose-embedded OB.  Consistent with the 
SEM analysis, statistically significant size differences were observed between the OB 
sizes of AcMNPV E2 and the bacmid-derived viruses (Ac23null and Acbacmid, Fig. 3.3).  
The mean size of the widest section of AcMNPV E2 OBs are greater than that of 
Acbacmid (2.39 ± 0.65 vs. 1.87 ± 0.41 µm, p < 0.0001) and Ac23null mutant (2.39 ± 0.65 
vs. 1.71 ± 0.46 µm, p < 0.0001).  Thus, both SEM and TEM analysis indicate that 
bacmid-derived OBs were on average smaller than those from wildtype AcMNPV E2, 
from which the bacmid was derived.  However, the size of OBs from the Ac23null mutant 
is not significantly different from the size of OBs from bacmid-derived Ac23-containing  
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Fig. 3.1 Diagram comparing the differences between the Ac23null virus and three control 
viruses. The differences occur at the Ac23 locus and the polyhedrin locus.  There are no 
modifications to the Ac23 locus in the AcMNPV E2 virus and the Acbacmid virus, but the 
Ac23 gene in both Ac23null and Ac23null-repair was replaced by a CAT gene.  There are 
no modifications in the polyhedrin locus of the AcMNPV E2 virus, but all three bacmid-
derived viruses (Acbacmid, Ac23null, Ac23null-repair) are polyhedrin gene-negative due 
to replacement of the polyhedrin gene with a cassette containing the mini-F replicon, a 
kanamycin resistance gene, and a mini-attTn7 site for accepting Tn7 mediated 
transposition (Luckow, 1993).  Two types of transfer vectors were used to insert genes 
into the polyhedrin locus by Tn7 mediated transposition.  Type I vectors were used to 
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insert genes into the Acbacmid and Ac23 null bacmid, and contained a GUS reporter gene 
under the control of a P6.9 promoter and a polyhedrin gene under the control of its own 
promoter.  Type II vector was used to generate the Ac23null-repair bacmid, and contained 
an Ac23 gene under the control of its own promoter in addition to the GUS and 
polyhedrin genes found in the type I vector. Abbreviations: polyh = polyhedrin promoter; 
Gmr = Gentamycin resistance marker; attTn7 = Tn7 attachment site. 
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Fig. 3.2 Scanning electron micrographs of occlusion bodies of A) AcMNPV E2, B) 
Acbacmid, C) Ac23null-repair, and D) Ac23null viruses. Scale bars = 1µm. 
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Fig. 3.3 Comparison of occlusion body size by analysis of scanning electron micrographs 
(SEM) and transmission electron micrographs (TEM).  Each bar represents the average of 
L1 and L2 OB diameters, and the error bars represent the standard deviation.  Significant 
size differences were found between wildtype OBs and OBs from the bacmid-derived 
viruses using the ANOVA test and Tukey test (p<0.0001).  No significant differences in 
the sizes of OB were found between Acbacmid, Ac23null-repair and Ac23null mutant. 
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control viruses. 
 
3.3.2. A significant and positive relationship was found between the number of ODV 
and the widest section of OB. 
To examine whether the number of occluded ODVs within OBs differed between 
Ac23null and control viruses, the section with widest diameter of 47 AcMNPV E2 OBs, 
37 Acbacmid OBs, and 26 Ac23null mutant OBs were used to determine the number of 
ODVs present in the section.  The number of ODVs per widest dimension of OB serial 
section varied between different OBs of the same genotype.  However, the average ODV 
numbers in the widest OB sections were similar among the three types of viruses 
(Ac23null: 18.58 ODVs/section, SD=12.51; Acbacmid: 18.68 ODVs/section, SD=10.5; 
AcMNPV E2: 19.96 ODVs/ section, SD=11.08).  The number of ODV particles within 
the section is positively correlated with the size of the widest OB section for all three 
viruses (Pearson correlation coefficient:  Ac23null virus r = 0.50, p = 0.007; Acbacmid r = 
0.37, p = 0.024; AcMNPV E2 r = 0.51, p =0.0002).  The size of the widest OB section 
was a significant and positive predictor of ODV number (Fig. 3. 4) in Ac23null (mean ± 
SE, β = 14.74 ± 5.06, p = 0.007), Acbacmid (β = 10.23 ± 4.28, p = 0.02), and AcMNPV 
E2 (β = 8.94 ± 2.24, p = 0.0002) virus.  The goodness of fit (R2) of the regression model 
was 25.4% for Ac23null, 14.0% for Acbacmid, and 26.2% for AcMNPV E2.  Extreme 
examples of the widest section of two different similarly sized OBs with dramatically 
different ODV numbers are shown in Fig. 3.5.  This variability may be partially explained 
by the low R2 of the regression model.  Determining the exact number of ODVs present 
in an entire OB by examination of serial section series was not possible because of the 
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reduced resolution and contrast due to the formvar and carbon films necessary for serial 
section support.  However, we consistently find that ODV abundance is comparable 
throughout the serial section series of any particular OB with the exceptions of the ends.  
These results suggest that the ODV number calculated in the widest OB section is a good 
indicator of the abundance of ODVs in a particular OB, and there are likely no significant 
differences on average between the ODV number of Ac23null OBs and Acbacmid control 
OBs. 
 
3.3.3. Nearly forty-five percent of Ac23-null mutant ODV contains a single 
nucleocapsid. 
Since no significant difference was found in the size and ODV content of Ac23null OBs 
and the bacmid-derived control OBs, we examined whether nucleocapsid numbers within 
Ac23null mutant ODVs differed from ODVs produced by Ac23-containing viruses.  
Transverse sections of a total of 337 AcMNPV E2 ODVs, 376 Acbacmid ODVs, 326 
Ac23null-repair ODVs, and 289 Ac23null mutant ODVs were analyzed to determine the 
number of nucleocapsids enclosed within them using electron micrographs (Table 3.1 and 
3.2).  The results show a significant difference in the nucleocapsid numbers found within 
ODV particles of the different genotypes.  A very high percentage (44.6%) of Ac23null 
mutant ODVs contains a single nucleocapsid.  In contrast, the percentage of single 
nucleocapsids in the controls, Ac23null-repair ODV (11.3%), Acbacmid ODV (21.8%) 
and AcMNPV E2 (13.6%) ODV are significantly lower.  The opposite trend was observed 
when the percentages of ODV containing five or more nucleocapsids were compared 
(Ac23null mutant, 17%; Ac23null-repair 49.7%; Acbacmid, 39.4%; AcMNPV E2, 55%,  
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Fig. 3.4 Scatter plot of occlusion body sizes versus ODV numbers of A) AcMNPV E2, B) 
Acbacmid, and C) Ac23null viruse. The data graphed represents a subset of the widest OB 
sections, which ODV number can be accurately determined. 
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Fig. 3.5 Extreme examples of two different wildtype AcMNPV OBs showing the 
variations between OB size and ODV number.  A) The widest serial section of OB with 
17 ODV, and B) the widest serial section from a different OB with no ODV, C) a 
schematic diagram illustrating the relationship between OB and its components. 
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Table 3.1).  The maximum nucleocapsid number that can be clearly distinguished in an 
Ac23null mutant ODV on micrographs was seven (1.8% of the total Ac23null ODV 
examined), however, ODVs with up to fifteen clearly distinguishable nucleocapsids can 
be observed in all three types of Ac23 containing viruses (Table 3.2).  Very rarely, ODVs 
of Ac23null and Ac23 containing viruses with more than 15 nucleocapsids were observed 
in the sections with the electron microscope (data not shown), however the exact 
nucleocapsid number in such ODVs cannot be determined from the micrographs.  
Consistent with the result that Ac23null ODVs contained mostly single or double 
nucleocapsids, a higher percentage (43%) of Ac23null OB sections on the micrographs 
only contained ODVs with nucleocapsid numbers of three or less.  In contrast, 23.4%, 
30.96% and 14.58% of the Ac23null-repair, Acbacmid and wt AcMNPV OB sections 
examined contained only ODVs with 1-3 nucleocapsids, respectively.  Thus, since the 
ODV number within the widest OB section are not significantly different among all 
viruses OB, the data suggest that Ac23null OBs contain significantly fewer nucleocapsids 
per OB than Ac23-containing control OBs.   
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Table 3.1 Frequency distribution of nucleocapsid number enclosed within Ac23null 
mutant and control virus ODV. 
 
 
 
 
  nucleocapsid number 
Virus 1 2 3 4 
5 or 
more 
Ac23null ODV (n=289) 44.6%  
(129) 
14.2%  
(41) 
12.1%  
(35) 
12.1%  
(35) 
17%  
(49) 
Ac23null-repair ODV (n=326) 11.3%  
(37) 
15.3%  
(50) 
12%  
(39) 
11.7%  
(38) 
49.7%  
(162) 
Acbacmid ODV (n=376) 21.8%  
(82) 
14.6%  
(55) 
14.4%  
(54) 
9.8%  
(37) 
39.4%  
(148) 
AcMNPV E2 ODV (n=337) 13.6%  
(46) 
8.3%  
(28) 
8.6%  
(29) 
14.5%  
(49) 
55%  
(185) 
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Table 3.2 Frequency distribution of nucleocapsids in ODV that contain 5 or more nucleocapsids. 
 
 
 
 
 
 
 
 
                  *nucleocapsid number greater than five, but the exact number can not be determined  
Virus capsid number unclear 5 
 5 6 7 8 9 10 11 12 13 14 15 16 or more* 
Ac23null (n=49) 
 
3.1% 
(9) 
2.4% 
(7) 
1.7% 
(5) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 9.7% 
                   (28) 
Ac23null-repair(n=162) 
 
6.7% 
(22) 
4% 
(13) 
3.7% 
(12) 
1.5% 
(5) 
0.3% 
(1) 
0.9% 
(3) 
0.6% 
(2) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0.3% 
(1) 31.6% 
                  (103) 
Acbacmid  (n=148) 
 
8.8% 
(33) 
1.9% 
(7) 
2.7% 
(10) 
0.8% 
(3) 
0% 
(0) 
1.1% 
(4) 
0.8% 
(3) 
0.3% 
(1) 
0.3% 
(1) 
0% 
(0) 
0.3% 
(1) 
0.3% 
(1) 24.2% 
                   (91) 
AcMNPV E2 (n=185) 
 
4.5% 
(15) 
5% 
(17) 
1.8% 
(6) 
1.8% 
(6) 
0.6% 
(2) 
0.6% 
(2) 
0.6% 
(2) 
0% 
(0) 
0.3% 
(1) 
0% 
(0) 
0.3% 
(1) 
0% 
(0) 
39.5% 
(133) 
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3.3.4. Nucleocapsid distribution pattern. 
The rod-shaped ODV nucleocapsids are typically bundled together lengthwise and 
examination of a large number of ODV cross sections on the micrographs show that the 
majority of ODVs with fewer than 11 nucleocapsids have a specific nucleocapsid 
arrangement pattern (Fig. 3.6).  Nucleocapsids in two-nucleocapsid ODVs are always 
arranged side-by-side (Fig. 3.6B, n=174); when a third nucleocapsid is present, the 
nucleocapsids are always arranged in a 1-2 triangular pattern (Fig. 3.6C, n=157); when 
four nucleocapsids are present, the nucleocapsids always form a 1-2-1 rhombus pattern 
(n=159).  Most of these rhombus-shaped ODVs form lozenges (Fig. 3.6D, n=137), but 
some appear rounder and are more like squares (n=22).  When five nucleocapsids are 
present these nucleocapsids usually form a 2-3 isosceles trapezoid and appear to be 
modified from a four nucleocapsid lozenge (Fig. 3.6E, n=73), while a small percentage 
forms a 1-2-2 irregular pentagon that appears to be modified from a four nucleocapsid 
square (n=6).  In six nucleocapsid ODVs, the nucleocapsids almost always form a 1-3-2 
irregular pattern (Fig, 3.6F, n=43), while a very small percentage formed a 1-2-3 
equilateral triangle (n=1).  Seven nucleocapsid ODVs always form a 2-3-2 hexagon (Fig. 
3.6G, n=33).  Eight nucleocapsid ODVs form a 1-2-3-2 irregular pattern (Fig. 3.6H, 
n=14), which appears to be a seven nucleocapsid ODV with an additional nucleocapsid 
positioned on one side of the seven-nucleocapsid hexagon.  Among three ODVs with 
nine nucleocapsids found on the micrographs, two of them formed an irregular 2-4-3 
pattern (Fig. 3.6I), while the other formed an irregular 3-3-3 pattern.  Both of these 
patterns have a concave spot that can be filled by a tenth nucleocapsid to form the same 
3-4-3 regular hexagon pattern (Fig. 3.6J, n=9).  In eleven-nucleocapsid ODV’s, the 
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eleventh nucleocapsid is positioned either along the longer side of the hexagon (Fig. 
3.6K, n=6) to form a 3-4-3-1 irregular pattern, or the shorter side of the hexagon to form 
a 3-4-4 irregular pattern (n=1).  From the electron micrographs, relatively few ODVs 
examined have more than eleven nucleocapsids that can be determined precisely (Fig. 
3.6L-O, n=7).  Additional patterns of 5, 6, 8, 9, 11 nucleocapsids ODVs were 
occasionally observed in sections under EM (data not shown).  No differences in 
nucleocapsid arrangement patterns were observed between ODVs from Ac23null and 
ODVs from control viruses. 
 
3.3.5. Ac23-GFP localizes to the nuclear membrane. 
Two recombinant baculovirus carrying a Ac23-GFP transgene were used to examine the 
localization of Ac23 in infected cells by confocal microscopy.  As expected for an 
envelope protein that is present on BVs, cells infected with the Ac23-GFP expressing 
viruses showed Ac23-GFP fluorescence at the plasma membrane and the cytoplasm of 
many infected cells (Fig. 3.7).  However, Ac23-GFP fluorescence also showed strong 
localization at the nuclear envelope of infected cells and in many cases, the nuclear 
envelope localization at 48 hpi is much more prominent than localization at the plasma 
membrane (see Fig. 3.7).  Since the nuclear envelope is the most likely source of ODV 
envelope, the localization of Ac23-GFP to the nuclear envelope is consistent with Ac23 
playing a role in the envelopment of ODV nucleocapsids.   
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Fig. 3.6 Nucleocapsid organization in ODV containing different numbers of 
nucleocapsids. Representative example of transverse sections of ODV containing A) 1, 
B) 2, C) 3, D) 4, E) 5, F) 6, G) 7, H) 8, I) 9, J) 10, K) 11, L) 12, M) 13, N) 14, and O) 15 
nucleocapsids.   
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Fig. 3.7 Ac23-GFP protein localizes to the nuclear envelope of infected cells.  Confocal 
images of Sf9 cells that were infected with either of two Ac23-GFP expressing viruses:  
Ac23null-Ac23GFP repair virus (48 hpi:  A - D; 77 hpi:  E - H), and Acbacmid-Ac23GFP 
virus (I – L, 48 hpi), or infected with a control GFP-minus virus Ac23null-repair (M – P, 
48 hpi), or mock infected (Q - T).  DIC images are shown in panels A, E, I, M, Q; GFP 
 
 
                      (48hpi) 
 
Ac23null-Ac23GFP 
                
                      (77hpi) 
            
 
 
 
 
 
Acbacmid-Ac23GFP 
                      (48hpi) 
 
 
 
         Ac23null-repair 
                      (48hpi) 
 
 
 
 
                        Mock 
       DIC                   GFP                DAPI                Merge 
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fluorescence is shown in panels B, F, J, N, R; DAPI fluorescence is shown in panels C, 
G, K, O, S; and images of all three channels merged are shown in panels D, H, L, P, T. 
3.4 Discussion 
 
Two different types of envelope fusion proteins (GP64 and F) have been identified in the 
baculovirus.  Analysis of sequenced baculovirus genomes (Hiscock et al., 2000) revealed 
that a small number of closely related baculovirus (group I NPVs) have both gp64 gene, 
and an f gene; most baculovirus (group II NPVs, GVs and a Diptera NPV) contain no 
gp64 gene, but have an f gene; and hymenopteran baculovirus (NeabNPV, NeseNPV, and 
NeleNPV) do not appear to have either gene (Duffy et al., 2006; Garcia-Maruniak et al., 
2004; Lauzon et al., 2004).  The presence of f gene homologs in viruses with a functional 
gp64 fusion protein gene such as AcMNPV and OpMNPV is intriguing, especially since 
the F homologs in AcMNPV (Ac23) and OpMNPV (Op21) do not have detectable 
membrane fusion activity in membrane syncytium assays (Lung et al., 2003; Pearson et 
al., 2000).  Pearson and Rohrmann (2002) proposed that f genes encode the prototypical 
BV envelope fusion protein and that group I NPVs acquired the gp64 gene more recently.  
The acquisition of gp64 subsequently displaced the membrane fusion function of the F 
protein in the group I NPVs.  The lack of membrane fusion activity in Ac23 and Op21 
may be due to the absence of a furin-cleavage site, which has been shown to be essential 
for membrane fusion activity of the SeMNPV F protein (Lung et al., 2003; Westenberg et 
al., 2002).  Characterization of an Ac23null mutant AcMNPV virus showed that this gene 
is not essential for viral infectivity in cultured cells or in animals (Lung et al., 2003).  
However, Ac23null mutant OBs had a slower speed of kill.  Results presented in the 
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current study show that the Ac23null mutant OBs were on average: 1) similar in size to 
bacmid-derived control OBs, 2) had comparable numbers of ODVs per OB as the control 
OBs, and 3) contained a significantly higher percentage of ODVs with single 
nucleocapsid (44.5% in the null mutant vs. 11.3% in the near isogenic control).  These 
results suggest that Ac23null OBs contain ODVs with fewer nucleocapsids than control 
OBs.  Detailed analysis of nucleocapsid arrangement in ODVs in this study suggests that 
the spatial organization of nucleocapsids is similar between ODVs from Ac23null and 
control viruses.  The spatial organization of nucleocapsids within AcMNPV ODVs with 
1, 2, 3, 7, and 10 nucleocapsids are similar to those described for Euproctis similes NPV 
(EusiNPV) (Kawamoto et al., 1974).  Nucleocapsid arrangement patterns not described 
by Kawamoto and Asayama for EusiNPV were observed in AcMNPV ODVs with 4, 5, 6, 
8, 9 and 11 nucleocapsids. 
 
When ODVs fuse with midgut cells, their nucleocapsids are transported to the nucleus 
where they unpackage their genomes and begin viral replication.  Progeny virus 
nucleocapsids are produced in the nucleus and are transported to the basolateral side of 
the cell membrane where they bud out as BVs.  When multiple ODV nucleocapsids are 
delivered to midgut cells an alternate pathway of infection may occur (Adams et al., 
1977; Granados et al., 1981).  In the alternate pathway some ODV nucleocapsids bypass 
the nucleus and migrate directly to the basolateral membrane.  Other ODV nucleocapsids 
enter the nucleus, unpackage their genomes and express gp64 which has an early 
promoter motif (Blissard and Rohrmann, 1991).  GP64 proteins are transported to the 
basolateral membrane and enable ODV-derived nucleocapsids to bud out as BV.  This 
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alternative pathway accelerates the progression of infection in the host by many hours 
(Adams et al., 1977; Granados et al., 1981).  Animals infected with Ac23null mutant OBs 
may have survived longer than those infected with control OBs in part because Ac23null 
viruses had fewer ODV nucleocapsids for the faster alternative pathway of infection.  The 
packaging of multiple nucleocapsids into virions is a hallmark of MNPVs, and has been 
suggested to offer a selective advantage over baculovirus that package a single 
nucleocapsid per virion (SNPV) (Washburn et al., 1999, 2003).  Recently, it was reported 
that Ac142 is essential for nucleocapsid evelopment to form ODV (McCarthy et al., 
2008).  The observation in this study that Ac23null ODVs with high nucleocapsid counts 
are present, and that the percentage of Ac23null ODVs with 2 – 4 nucleocapsid counts are 
comparable to the controls suggests that Ac23 is not essential for multiple nucleocapsid 
envelopment, but it might somehow facilitate multiple nucleocapsid envelopment. 
 
Consistent with Ac23 playing a role in the envelopment of ODV nucleocapsids, Ac23 
was recently identified as a component of the ODV, and proposed to be an ODV envelope 
protein (Braunagel et al., 2003).  The source of the ODV envelope has not yet been 
conclusively demonstrated, but the nuclear membrane is considered a likely source.  
Thus, my observation that Ac23 localizes to the nuclear membrane is consistent with 
Ac23 being not only a BV envelope protein, but also an ODV envelope protein, and it 
may plays a role in the envelopment of ODV nucleocapsids.  Conceptual translation of 
the Ac23 protein sequence reveals the presence of a putative nuclear localization signal 
(PKKKFNF) at position 513-519 of the protein that may be involved in nuclear envelope 
localization.  Ac23 also has a putative long C-terminal tail that could play a role in ODV 
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nucleocapsid envelopment by physically interacting with ODV nucleocapsid components 
(data not shown).  Whether Ac23 interacts with the major capsid protein VP39 or other 
capsid associated proteins such as p80, p24, and/or orf1629 (pp78/83) to influence ODV 
nucleocapsid envelopment remains to be determined.  Since Ac23 has also been shown to 
be associated with BV (Lung et al., 2003), and since most BVs contain single 
nucleocapids, factors in the BV membrane (e.g. GP64), BV nucleocapsid or the 
cytosol/plasma membrane may inhibit Ac23 promotion of multiple capsid packaging in 
BVs.  It should however be noted that multiple capsid AcMNPV BVs have been observed 
under EM (Adams et al., 1991).  Alternatively, unidentified factors found exclusively in 
the ODV membrane, ODV nucleocapsid or the nucleus could be enabling Ac23 to 
promote envelopment of multiple nucleocapsids into the ODV.  In SNPVs, the F 
homologues and/or their interaction partners may have enough sequence divergence to 
prevent the envelopment of multiple capsids into a single ODV.  Consistent with this 
hypothesis, F homologues from even the most closely related group I NPVs with 
sequence available are poorly conserved.  For example, amino acid identity between the 
mature (without the predicted signal sequence) Ac23 and the Op21 protein from 
OpMNPV is only approximately 47.9%, while the percent identity between mature Ac23 
and Bm14 from BmNPV (an MNPV) is only 37.6%.  Single step growth curve analysis 
performed in Sf9 cells suggests that the Ac23null mutant BV have slightly slower growth 
kinetics in the first 24 hr post infection when compared to control viruses (Lung et al., 
2003).  In both Sf9 and High-5 cells, and at all time points examined, progression of 
infections in Ac23null BV infected cells is slower than control BV infected cells.  These 
observations indicate that Ac23 also enhance BV infection, perhaps by promoting binding 
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to cell surface receptors and facilitating viral entry. 
 
In GP64 containing viruses, it appears that F protein has been retained to perform 
multiple auxiliary functions.  Ac23 appears to play distinctive roles in the BV and in the 
ODV.  Generation of ODVs with higher nucleocapsid numbers could facilitate rapid 
establishment of primary infection, while facilitating BV infection promotes progeny 
virus production, systemic infection and OB formation.  In contrast, GP64 has been 
shown to be associated exclusively with BVs (Blissard et al., 1989).  These intriguing 
observations further support the contention that the F protein plays a different role from 
that of GP64 in viruses that contain both proteins.  Whether Ac23 has an effect on BV or 
ODV binding to cell surface receptors or ODV fusion with midgut cells, in addition to its 
role in ODV assembly, remains to be determined. 
 
F protein is likely to have evolved in baculovirus genomes over a longer period of time 
than the more recently acquired GP64.  Thus it is not surprising to discover that F 
proteins may have evolved pleotrophic functions beyond envelope fusion.  My data 
suggest that although Ac23 is a nonessential gene, its effects on nucleocapsid packaging 
in ODVs, and BV spread could offer significant selective advantages to AcMNPV. 
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Conclusion 
 
Enveloped viruses, such as baculoviruses, require fusion proteins on the viral envelope 
for cell recognition and entry.  Two different types of envelope fusion proteins have so 
far been identified in baculoviruses.  GP64 is a well characterized low pH-activated 
fusion protein that is found in a relatively small group of baculovirus (group I NPVs) in 
which AcMNPV belongs.  AcMNPV is unique among baculoviruses in that it can enter a 
variety of cell types, including non-host cells such as human hepatocytes.  This is likely 
due to the presence of GP64 on the virion.  F (fusion) proteins are found in both group I 
and group II NPVs, but so far fusion activity have only been demonstrated for F proteins 
from group II NPVs.     
   
In chapter two of this thesis I examined the significance of GP64 and the SeF (F protein 
from SeMNPV) in mediating viral entry into vertebrate cells, and evaluated the 
possibility of developing a gp64null AcMNPV vector with minimal tropism for non-
insect cells.  The transduction efficiency of the genetically engineered AcMNPV variants 
that either have the endogenous GP64 envelope protein, or the SeF protein, or have both 
GP64 and SeF were evaluated on 15 different vertebrate cell lines.  I have shown that 
transduction efficiency of SeF-pseudotyped gp64null AcMNPV on HepG2, BHK-21, PK-
15 and FKC cells were at least 50 fold lower than that of the GP64-containing control 
viruses.  Transduction efficiency for human HepG2 dropped dramatically from 
approximately 98% to approximately 0.15% when vgp64nullAcSeF-CMV-hrGFP was used in 
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place of vgp64nullAcGP64-CMV-hrGFP.  Except for the three fish-derived cell lines, 
transduction efficiencies of SeF-pseudotyped gp64null virus were lower than 1% on all 
cell lines tested.  These results indicate that the tropism of AcMNPV virus for vetebrate 
cells can be restricted by pseudotyping a gp64null virus with SeF.  Thus, the SeF-
pseudotyped gp64null vector may be a useful platform for incorporation of additional 
targeting molecules for targeted gene delivery.  Low levels of transduction (0.2%) by the 
SeF-pseudotyped gp64null virus was observed with 4 mammalian cell lines.  These low 
level transductions can be further eliminated by using a lower virus to cell ratio, or 
potentially also by using engineered SeF proteins that contain mutations such as 
truncations in the ectodomain.  My results also indicated that GP64 is a critical factor for 
efficient transduction of vertebrate cells by AcMNPV.  Five recombinant bacmids with 
CMV-luciferase cassettes in place of the CMV-hrGFP cassettes were also generated, but 
have not been made into viruses and used in evaluation of transduction (described in 
materials and methods section of chapter 2).  These reagents could be used in the future 
for a more quantitative examination of AcMNPV-mediated gene expression in cell lines 
and for in vivo animal studies.   
 
During the course of this study I also made the interesting observation that GP64 can 
mediate cell-cell fusion in the absence of low pH-activation in SCP and MDBK cells.  To 
my knowledge this phenomenon has not been previously reported, and suggest there are 
alternative mechanisms (pH-independent) that can activate the membrane fusion activity 
of GP64.  The biological significance of this phenomenon and the mechanism by which 
GP64 can be activated at neutral pH remains to be determined. 
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The function of the AcMNPV F homolog (Ac23) is unclear, since Ac23 does not have 
detectable membrane fusion activity, and is not required for AcMNPV propagation and 
pathogenicity.  The presence of this gene in the AcMNPV genome and the fact that it is 
expressed and incorporated into virions strongly suggest the Ac23 gene or its gene 
product likely offer significant selective advantage to this virus.  Previous reports have 
shown Ac23 to be a pathogenicity factor that increases AcMNPV’s speed of kill.  
However, the mechanism by which Ac23 accelerates host death is unclear.  Chapter 3 of 
this thesis describes a comparison of occlusion bodies (OB) and occlusion derived virus 
(ODV) made by an Ac23null mutant and those from control viruses.  My results show 
that while OB size and the number of ODV per OB were comparable, 44.6% of Ac23null 
virus ODVs contain single nucleocapsid per ODV in comparison to the 11.3% found in 
the near isogenic control (Ac23null-repair) ODVs.  This observation suggests that Ac23 
could some how facilitate the incorporation of multiple nucleocapsids into each ODV 
particle.  Since nucleocapsid number is equal to the genome copy number, Ac23null 
ODVs (the infectious unit of AcMNPV) contains less genome copies than viruses with 
the Ac23 gene intact.  This result suggest that Ac23 OBs and ODVs have fewer 
nucleocapsids than wildtype viruses, and this would in turn make establishment of 
secondary and systemic infections more time consuming as the virions can not utilize the 
more rapid, alternative route of infection (see Discussion of chapter 3), and would thus 
result in a slower speed of kill.   
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Previous reports that Ac23 is an ODV envelope protein, and my observation that Ac23-
GFP fusion protein localizes to the nuclear membrane of the infected cell (a likely source 
of the ODV envelope), suggest that Ac23 might be interacting directly with nucleocapsid 
proteins to promote nucleocapsid envelopment.   Whether Ac23 interacts with the major 
capsid protein VP39 or other proteins remains to be determined.  In combination with 
previous reports that Ac23 is detected on the BV envelope, and may affect the production 
of infectious BV, these results indicate that F proteins have evolved functions beyond 
envelope fusion and play a different role from that of GP64 in viruses that contain both 
proteins.  This result also support the hypothesis that packaging multiple nucleocapsids in 
virions and the retention of a non-essential F homolog offers selective advantage to this 
multicapsid nucleopolyhedrovirus.   
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